BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 381] [Article Influence: 138.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhong YB, Kang ZP, Zhou BG, Wang HY, Long J, Zhou W, Zhao HM, Liu DY. Curcumin Regulated the Homeostasis of Memory T Cell and Ameliorated Dextran Sulfate Sodium-Induced Experimental Colitis. Front Pharmacol 2020;11:630244. [PMID: 33597887 DOI: 10.3389/fphar.2020.630244] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Peng S, Shen L, Tian MX, Li HM, Wang SS. Poly(ADP-ribose) polymerase-1 inhibitor ameliorates dextran sulfate sodium-induced colitis in mice by regulating the balance of Th17/Treg cells and inhibiting the NF-κB signaling pathway. Exp Ther Med 2021;21:134. [PMID: 33376516 DOI: 10.3892/etm.2020.9566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Xue G, Hua L, Zhou N, Li J. Characteristics of immune cell infiltration and associated diagnostic biomarkers in ulcerative colitis: results from bioinformatics analysis. Bioengineered 2021;12:252-65. [PMID: 33323040 DOI: 10.1080/21655979.2020.1863016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
4 Yang Y, Zhang Y. Acute transverse myelitis in an adult-patient with underlying ulcerative colitis: a case report. BMC Gastroenterol 2022;22:161. [PMID: 35365068 DOI: 10.1186/s12876-022-02230-z] [Reference Citation Analysis]
5 Lu J, Liu D, Tan Y, Deng F, Li R. M1 Macrophage exosomes MiR-21a-5p aggravates inflammatory bowel disease through decreasing E-cadherin and subsequent ILC2 activation. J Cell Mol Med 2021;25:3041-50. [PMID: 33569850 DOI: 10.1111/jcmm.16348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhao J, Zhang B, Mao Q, Ping K, Zhang P, Lin F, Liu D, Feng Y, Sun M, Zhang Y, Li QH, Zhang T, Mou Y, Wang S. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem 2022. [PMID: 35275619 DOI: 10.1021/acs.jmedchem.1c02166] [Reference Citation Analysis]
7 Zhao L, Tian W, Qu W, Li T, Zhu J, Ma H, Cai S. Protease Hydrolysates Ameliorates Inflammation and Intestinal Flora Imbalance in DSS-Induced Colitis Mice. Journal of Food Quality 2021;2021:1-11. [DOI: 10.1155/2021/5536148] [Reference Citation Analysis]
8 Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol. 2020;13:1756284820915043. [PMID: 32523620 DOI: 10.1177/1756284820915043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ma X, Xu H, Zhang D. Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis. BMJ Open 2021;11:e055182. [DOI: 10.1136/bmjopen-2021-055182] [Reference Citation Analysis]
10 Wang B, Gong Z, Zhan J, Yang L, Zhou Q, Yuan X. Xianglian Pill Suppresses Inflammation and Protects Intestinal Epithelial Barrier by Promoting Autophagy in DSS Induced Ulcerative Colitis Mice. Front Pharmacol 2020;11:594847. [PMID: 33584273 DOI: 10.3389/fphar.2020.594847] [Reference Citation Analysis]
11 Kjærgaard S, Damm MMB, Chang J, Riis LB, Rasmussen HB, Hytting-Andreasen R, Krug SM, Schulzke JD, Bindslev N, Hansen MB. Altered Structural Expression and Enzymatic Activity Parameters in Quiescent Ulcerative Colitis: Are These Potential Normalization Criteria? Int J Mol Sci 2020;21:E1887. [PMID: 32164249 DOI: 10.3390/ijms21051887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kaiko GE, Chen F, Lai CW, Chiang IL, Perrigoue J, Stojmirović A, Li K, Muegge BD, Jain U, VanDussen KL, Goggins BJ, Keely S, Weaver J, Foster PS, Lawrence DA, Liu TC, Stappenbeck TS. PAI-1 augments mucosal damage in colitis. Sci Transl Med 2019;11:eaat0852. [PMID: 30842312 DOI: 10.1126/scitranslmed.aat0852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
13 Lai L, Li H, Feng Q, Shen J, Ran Z. Multi-factor mediated functional modules identify novel classification of ulcerative colitis and functional gene panel. Sci Rep 2021;11:5669. [PMID: 33707495 DOI: 10.1038/s41598-021-85000-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Thomsen SB, Ungaro RC, Allin KH, Elmahdi R, Poulsen G, Andersson M, Colombel JF, Jess T. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study. Aliment Pharmacol Ther 2022. [PMID: 35080036 DOI: 10.1111/apt.16777] [Reference Citation Analysis]
15 Gu L, Ren F, Fang X, Yuan L, Liu G, Wang S. Exosomal MicroRNA-181a Derived From Mesenchymal Stem Cells Improves Gut Microbiota Composition, Barrier Function, and Inflammatory Status in an Experimental Colitis Model. Front Med (Lausanne) 2021;8:660614. [PMID: 34249964 DOI: 10.3389/fmed.2021.660614] [Reference Citation Analysis]
16 Huo JH, Wang XY, Gong L, Gu X. Role of regulatory B cells in autoimmune diseases of the digestive system. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 486-492 [DOI: 10.11569/wcjd.v28.i12.486] [Reference Citation Analysis]
17 Wu X, Xu N, Ye Z, Zhao Q, Liu J, Li J, Wu M, Zheng Y, Li X, Li W, Zhang T, Hu X, Zhang Q. Polysaccharide from Scutellaria barbata D. Don attenuates inflammatory response and microbial dysbiosis in ulcerative colitis mice. Int J Biol Macromol 2022:S0141-8130(22)00365-8. [PMID: 35218798 DOI: 10.1016/j.ijbiomac.2022.02.119] [Reference Citation Analysis]
18 Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov 2021;2:100070. [PMID: 34988431 DOI: 10.1016/j.crphar.2021.100070] [Reference Citation Analysis]
19 D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol 2019;12:1756284819848631. [PMID: 31205486 DOI: 10.1177/1756284819848631] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
20 Feng J, Chen Y, Feng Q, Ran Z, Shen J. Novel Gene Signatures Predicting Primary Non-response to Infliximab in Ulcerative Colitis: Development and Validation Combining Random Forest With Artificial Neural Network. Front Med (Lausanne) 2021;8:678424. [PMID: 34650991 DOI: 10.3389/fmed.2021.678424] [Reference Citation Analysis]
21 Zhang L, Wu YB, Dai YK, Liu Q, Ren YJ, Xu SJ, Pan HG, Chen WJ, Li RL, Hu L. Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis. PLoS One 2021;16:e0257599. [PMID: 34543327 DOI: 10.1371/journal.pone.0257599] [Reference Citation Analysis]
22 Ito N, Takeuchi I, Kyodo R, Hirano Y, Sato T, Usami M, Shimizu H, Shimizu T, Arai K. Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2021;24:357-65. [PMID: 34316470 DOI: 10.5223/pghn.2021.24.4.357] [Reference Citation Analysis]
23 Shi L, Han X, Li JX, Liao YT, Kou FS, Wang ZB, Shi R, Zhao XJ, Sun ZM, Hao Y. Identification of differentially expressed genes in ulcerative colitis and verification in a colitis mouse model by bioinformatics analyses. World J Gastroenterol 2020; 26(39): 5983-5996 [PMID: 33132649 DOI: 10.3748/wjg.v26.i39.5983] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wen S, He L, Zhong Z, Zhao R, Weng S, Mi H, Liu F. Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-PPARγ Axis in Colitis. Front Immunol 2021;12:741934. [PMID: 34691046 DOI: 10.3389/fimmu.2021.741934] [Reference Citation Analysis]
25 Rodrigues BL, Dotti I, Pascoal LB, Morari J, Esteller M, Coope A, Ayrizono MDLS, Salas A, Leal RF, Dalmarco E. Endoplasmic Reticulum Stress in Colonic Mucosa of Ulcerative Colitis Patients Is Mediated by PERK and IRE1 Pathway Activation. Mediators of Inflammation 2022;2022:1-13. [DOI: 10.1155/2022/6049500] [Reference Citation Analysis]
26 Zhang MN, Shi YD, Jiang HY. The risk of dementia in patients with inflammatory bowel disease: a systematic review and meta-analysis. Int J Colorectal Dis 2022. [PMID: 35325272 DOI: 10.1007/s00384-022-04131-9] [Reference Citation Analysis]
27 Burisch J, Ungaro R, Vind I, Prosberg MV, Bendtsen F, Colombel JF, Vester-Andersen MK. Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. J Crohns Colitis 2017;11:1200-4. [PMID: 28486626 DOI: 10.1093/ecco-jcc/jjx066] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
28 Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00134-7. [PMID: 35183439 DOI: 10.1016/j.dld.2022.01.123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Du H, Xia H, Liu T, Li Y, Liu J, Xie B, Chen J, Liu T, Cao L, Liu S, Li S, Wang P, Wang D, Zhang Z, Li Y, Guo X, Wu A, Li M, You F. Suppression of ELF4 in ulcerative colitis predisposes host to colorectal cancer. iScience 2021;24:102169. [PMID: 33665583 DOI: 10.1016/j.isci.2021.102169] [Reference Citation Analysis]
30 Liu J, Cai J, Fan P, Zhang N, Cao Y. The Abilities of Salidroside on Ameliorating Inflammation, Skewing the Imbalanced Nucleotide Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3/Autophagy, and Maintaining Intestinal Barrier Are Profitable in Colitis. Front Pharmacol. 2019;10:1385. [PMID: 31849652 DOI: 10.3389/fphar.2019.01385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
31 Wang Y, Cui B, Zhang F. Refractory ulcerative colitis stabilized by interval washed microbiota transplantation: less is more. Curr Med Res Opin 2022;:1-5. [PMID: 35040380 DOI: 10.1080/03007995.2022.2030563] [Reference Citation Analysis]
32 Wang G, Xu B, Shi F, Du M, Li Y, Yu T, Chen L. Protective Effect of Methane-Rich Saline on Acetic Acid-Induced Ulcerative Colitis via Blocking the TLR4/NF-κB/MAPK Pathway and Promoting IL-10/JAK1/STAT3-Mediated Anti-inflammatory Response. Oxid Med Cell Longev 2019;2019:7850324. [PMID: 31182999 DOI: 10.1155/2019/7850324] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
33 Wang T, Shi C, Wang S, Zhang Y, Wang S, Ismael M, Zhang J, Wang X, Lü X. Protective Effects of Companilactobacillus crustorum MN047 against Dextran Sulfate Sodium-Induced Ulcerative Colitis: A Fecal Microbiota Transplantation Study. J Agric Food Chem . [DOI: 10.1021/acs.jafc.1c07316] [Reference Citation Analysis]
34 Deng J, Wu Z, Zhao Z, Wu C, Yuan M, Su Z, Wang Y, Wang Z. Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis. Int J Nanomedicine 2020;15:3937-51. [PMID: 32581538 DOI: 10.2147/IJN.S247406] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
35 Caër C, Wick MJ. Human Intestinal Mononuclear Phagocytes in Health and Inflammatory Bowel Disease. Front Immunol 2020;11:410. [PMID: 32256490 DOI: 10.3389/fimmu.2020.00410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
36 Wei W, Mu S, Han Y, Chen Y, Kuang Z, Wu X, Luo Y, Tong C, Zhang Y, Yang Y, Song Z. Gpr174 Knockout Alleviates DSS-Induced Colitis via Regulating the Immune Function of Dendritic Cells. Front Immunol 2022;13:841254. [DOI: 10.3389/fimmu.2022.841254] [Reference Citation Analysis]
37 Singh A, Fenton CG, Anderssen E, Paulssen RH. Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis. Int J Colorectal Dis 2022. [PMID: 35543875 DOI: 10.1007/s00384-022-04176-w] [Reference Citation Analysis]
38 Uździcki AW, Wawrzynowicz-Syczewska M. Characteristic features of ulcerative colitis with concomitant primary sclerosing cholangitis. Prz Gastroenterol 2021;16:184-7. [PMID: 34584578 DOI: 10.5114/pg.2021.108983] [Reference Citation Analysis]
39 Li C. Unfolded Protein Response and Crohn’s Diseases: A Molecular Mechanism of Wound Healing in the Gut. GastrointestDisord 2021;3:31-43. [DOI: 10.3390/gidisord3010004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 He N, Yang Y, Wang H, Liu N, Yang Z, Li S. Unsaturated alginate oligosaccharides (UAOS) protects against dextran sulfate sodium-induced colitis associated with regulation of gut microbiota. Journal of Functional Foods 2021;83:104536. [DOI: 10.1016/j.jff.2021.104536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Song Y, Jiang K, Wang BM, Liu WT, Lin R. miR‑31 promotes tumorigenesis in ulcerative colitis‑associated neoplasia via downregulation of SATB2. Mol Med Rep 2020;22:4801-9. [PMID: 33173968 DOI: 10.3892/mmr.2020.11573] [Reference Citation Analysis]
42 Yu P, Ke C, Guo J, Zhang X, Li B. Lactobacillus plantarum L15 Alleviates Colitis by Inhibiting LPS-Mediated NF-κB Activation and Ameliorates DSS-Induced Gut Microbiota Dysbiosis. Front Immunol 2020;11:575173. [PMID: 33123156 DOI: 10.3389/fimmu.2020.575173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhong Y, Xiao Q, Li S, Chen L, Long J, Fang W, Yu F, Huang J, Zhao H, Liu D. Bupi Yichang Pill alleviates dextran sulfate sodium-induced ulcerative colitis in mice by regulating the homeostasis of follicular helper T cells. Phytomedicine 2022;100:154091. [PMID: 35395566 DOI: 10.1016/j.phymed.2022.154091] [Reference Citation Analysis]
44 Uzzan M, Martin JC, Mesin L, Livanos AE, Castro-dopico T, Huang R, Petralia F, Magri G, Kumar S, Zhao Q, Rosenstein AK, Tokuyama M, Sharma K, Ungaro R, Kosoy R, Jha D, Fischer J, Singh H, Keir ME, Ramamoorthi N, Gorman WEO, Cohen BL, Rahman A, Cossarini F, Seki A, Leyre L, Vaquero ST, Gurunathan S, Grasset EK, Losic B, Dubinsky M, Greenstein AJ, Gottlieb Z, Legnani P, George J, Irizar H, Stojmirovic A, Brodmerkel C, Kasarkis A, Sands BE, Furtado G, Lira SA, Tuong ZK, Ko HM, Cerutti A, Elson CO, Clatworthy MR, Merad M, Suárez-fariñas M, Argmann C, Hackney JA, Victora GD, Randolph GJ, Kenigsberg E, Colombel JF, Mehandru S. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. [DOI: 10.1038/s41591-022-01680-y] [Reference Citation Analysis]
45 Łukawska A, Ślósarz D, Zimoch A, Serafin K, Poniewierka E, Kempiński R. Cumulative Effective Dose from Medical Imaging in Inflammatory Bowel Disease. Diagnostics (Basel) 2021;11:2387. [PMID: 34943623 DOI: 10.3390/diagnostics11122387] [Reference Citation Analysis]
46 Kim JT, Napier DL, Kim J, Li C, Lee EY, Weiss HL, Wang Q, Evers BM. Ketogenesis alleviates TNFα-induced apoptosis and inflammatory responses in intestinal cells. Free Radic Biol Med 2021;172:90-100. [PMID: 34087430 DOI: 10.1016/j.freeradbiomed.2021.05.032] [Reference Citation Analysis]
47 Soendergaard C, Kvist PH, Thygesen P, Reslow M, Nielsen OH, Kopchick JJ, Holm TL. Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis. Int J Mol Sci. 2017;18:2046. [PMID: 28946616 DOI: 10.3390/ijms18102046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
48 Lo B, Burisch J. Artificial intelligence assisted assessment of endoscopic disease activity in inflammatory bowel disease. Artif Intell Gastrointest Endosc 2021; 2(4): 95-102 [DOI: 10.37126/aige.v2.i4.95] [Reference Citation Analysis]
49 Roosenboom B, Lochem EGV, Meijer J, Smids C, Nierkens S, Brand EC, Erp LWV, Kemperman LGJM, Groenen MJM, Horje CSHT, Wahab PJ. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells 2020;9:E891. [PMID: 32268498 DOI: 10.3390/cells9040891] [Reference Citation Analysis]
50 Rowan C, Ungaro R, Mehandru S, Colombel JF. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opin Pharmacother 2022. [PMID: 35503955 DOI: 10.1080/14656566.2022.2071605] [Reference Citation Analysis]
51 Folkerts J, Stadhouders R, Redegeld FA, Tam SY, Hendriks RW, Galli SJ, Maurer M. Effect of Dietary Fiber and Metabolites on Mast Cell Activation and Mast Cell-Associated Diseases. Front Immunol 2018;9:1067. [PMID: 29910798 DOI: 10.3389/fimmu.2018.01067] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
52 Bhandari R, Ogeyingbo OD, Kareem R, Gyawali M, Venkatesan N, Ahmed R, Botleroo RA, Elshaikh AO. Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review. Cureus 2021;13:e17729. [PMID: 34659943 DOI: 10.7759/cureus.17729] [Reference Citation Analysis]
53 Aoyama Y, Inaba T, Takahashi S, Yasuhara H, Hiraoka S, Morimoto T, Colvin HS, Wato M, Ando M, Nakamura S, Mizobuchi K, Okada H. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol 2021;21:325. [PMID: 34425765 DOI: 10.1186/s12876-021-01903-5] [Reference Citation Analysis]
54 Pakoz ZB, Ustaoglu M, Vatansever S, Yuksel ES, Topal F, Adani GL. Serum Immune-Inflammation Index Assessment in the Patients with Ulcerative Colitis. Gastroenterology Research and Practice 2022;2022:1-5. [DOI: 10.1155/2022/9987214] [Reference Citation Analysis]
55 Vollenberg R, Tepasse P, Lorentzen E, Nowacki TM. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. JPM 2022;12:694. [DOI: 10.3390/jpm12050694] [Reference Citation Analysis]
56 Navarrete J, González-moret R, Cortés X, Lisón JF, Soria JM, Baños RM, Cebolla A. Dispositional Mindfulness and Inflammatory Bowel Disease: Mindful Awareness Mediates the Relation Between Severity and Quality of Life, Stress, and Fatigue. Mindfulness 2021;12:1524-33. [DOI: 10.1007/s12671-021-01620-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Chen ZA, Sun YF, Wang QX, Ma HH, Ma ZZ, Yang CJ. Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Ulcerative Colitis. Front Genet 2021;12:697514. [PMID: 34306038 DOI: 10.3389/fgene.2021.697514] [Reference Citation Analysis]
58 Verstockt B, Parkes M, Lee J. How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments? Gastroenterology 2022:S0016-5085(21)04081-6. [PMID: 34995535 DOI: 10.1053/j.gastro.2021.12.245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
59 Lawton J, Achit H, Pouillon L, Boschetti E, Demore B, Matton T, Tournier C, Prodel M, Peyrin-Biroulet L, Guillemin F. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience. United European Gastroenterol J 2019;7:908-13. [PMID: 31428415 DOI: 10.1177/2050640619853448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
60 Li C, Wang J, Ma R, Li L, Wu W, Cai D, Lu Q. Natural-derived alkaloids exhibit great potential in the treatment of ulcerative colitis. Pharmacol Res 2021;175:105972. [PMID: 34758401 DOI: 10.1016/j.phrs.2021.105972] [Reference Citation Analysis]
61 Li K, Dong J, Ge D, Li M, Ye H, Wang X, Wu Y. The Effects of Sishen Wan on T Cell Responses in Mice Models of Ulcerative Colitis Induced by Dextran Sodium Sulfate. Evid Based Complement Alternat Med 2021;2021:9957709. [PMID: 34956391 DOI: 10.1155/2021/9957709] [Reference Citation Analysis]
62 Geng Y, Yue Y, Guan Q, Ren Y, Guo L, Fan Y, Lu ZM, Shi JS, Xu ZH. Cereal Vinegar Sediment Alleviates Spontaneous Ulcerative Colitis in Il-10 Deficient Mice. Mol Nutr Food Res 2021;:e2001227. [PMID: 34699119 DOI: 10.1002/mnfr.202001227] [Reference Citation Analysis]
63 Skamnelos A, Lazaridis N, Vlachou E, Koukias N, Apostolopoulos P, Murino A, Christodoulou D, Despott EJ. The role of small-bowel endoscopy in inflammatory bowel disease: an updated review on the state-of-the-art in 2021. Ann Gastroenterol 2021;34:599-611. [PMID: 34475730 DOI: 10.20524/aog.2021.0652] [Reference Citation Analysis]
64 Kayal M, Tixier E, Plietz M, Radcliffe M, Rizvi A, Riggs A, Trivedi P, Khaitov S, Sylla P, Greenstein A, Dubinsky MC, Grinspan A. Clostridioides Difficile Infection Is a Rare Cause of Infectious Pouchitis. Inflamm Intest Dis 2020;5:59-64. [PMID: 32596255 DOI: 10.1159/000505658] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Madarame A, Fukuzawa M, Yamauchi Y, Kono S, Sugimoto A, Yamaguchi H, Morise T, Koyama Y, Uchida K, Suguro M, Matsumoto T, Yasuyuki K, Kawai T, Itoi T. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. PLoS One 2021;16:e0255620. [PMID: 34347848 DOI: 10.1371/journal.pone.0255620] [Reference Citation Analysis]
66 Rodriguez-Canales M, Martinez-Galero E, Nava-Torres AD, Sanchez-Torres LE, Garduño-Siciliano L, Canales-Martinez MM, Terrazas LI, Rodriguez-Monroy MA. Anti-Inflammatory and Antioxidant Activities of the Methanolic Extract of Cyrtocarpa procera Bark Reduces the Severity of Ulcerative Colitis in a Chemically Induced Colitis Model. Mediators Inflamm 2020;2020:5062506. [PMID: 32377161 DOI: 10.1155/2020/5062506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
67 Bing X, Linlang L, Keyan C. Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis. Can J Gastroenterol Hepatol 2018;2018:5760849. [PMID: 29765931 DOI: 10.1155/2018/5760849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Molendijk I, van der Marel S, Maljaars PWJ. Towards a Food Pharmacy: Immunologic Modulation through Diet. Nutrients 2019;11:E1239. [PMID: 31159179 DOI: 10.3390/nu11061239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
69 De Santis S, Scarano A, Liso M, Calabrese FM, Verna G, Cavalcanti E, Sila A, Lippolis A, De Angelis M, Santino A, Chieppa M. Polyphenol Enriched Diet Administration During Pregnancy and Lactation Prevents Dysbiosis in Ulcerative Colitis Predisposed Littermates. Front Cell Infect Microbiol 2021;11:622327. [PMID: 34178715 DOI: 10.3389/fcimb.2021.622327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10. [PMID: 32180822 DOI: 10.7573/dic.2019-10-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
72 Wang X, Wan J, Wang M, Zhang Y, Wu K, Yang F. Multiple sclerosis and inflammatory bowel disease: A systematic review and meta‐analysis. Ann Clin Transl Neurol. [DOI: 10.1002/acn3.51495] [Reference Citation Analysis]
73 Long Y, He Y, Jie F, Li S, Wu Y, Li Y, Du Q. Kuijieling-Containing Serum Regulates Th17 and Treg Cell Differentiation by Inhibiting STAT3 Signaling In Vitro. Evid Based Complement Alternat Med 2019;2019:7837989. [PMID: 31534467 DOI: 10.1155/2019/7837989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, Rajkovic I, Milligan G. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol 2020;7:e000476. [PMID: 33199269 DOI: 10.1136/bmjgast-2020-000476] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00294-6. [PMID: 34798038 DOI: 10.1016/S2468-1253(21)00294-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
76 Núñez F P, Quera R, Rubin DT. Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget. World J Gastrointest Endosc 2022; 14(2): 85-95 [DOI: 10.4253/wjge.v14.i2.85] [Reference Citation Analysis]
77 Liu Y, Zhou M, Yang M, Jin C, Song Y, Chen J, Gao M, Ai Z, Su D. Pulsatilla chinensis Saponins Ameliorate Inflammation and DSS-Induced Ulcerative Colitis in Rats by Regulating the Composition and Diversity of Intestinal Flora. Front Cell Infect Microbiol 2021;11:728929. [PMID: 34804990 DOI: 10.3389/fcimb.2021.728929] [Reference Citation Analysis]
78 Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol 2017; 23(32): 5836-5848 [PMID: 28932076 DOI: 10.3748/wjg.v23.i32.5836] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 25] [Article Influence: 9.6] [Reference Citation Analysis]
79 Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, Benvenuti L, Facchin S, D'antongiovanni V, Lorenzon G, Ceccarelli L, Baglietto L, de Bortoli N, Bellini M, Costa F, Savarino EV, Fornai M. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.008] [Reference Citation Analysis]
80 Chen Y, Chen H, Ding J, Stanton C, Ross RP, Zhao J, Zhang H, Yang B, Chen W. Bifidobacterium longum Ameliorates Dextran Sulfate Sodium-Induced Colitis by Producing Conjugated Linoleic Acid, Protecting Intestinal Mechanical Barrier, Restoring Unbalanced Gut Microbiota, and Regulating the Toll-Like Receptor-4/Nuclear Factor-κB Signaling Pathway. J Agric Food Chem 2021;69:14593-608. [PMID: 34843239 DOI: 10.1021/acs.jafc.1c06176] [Reference Citation Analysis]
81 Li R, Huang X, Yang L, Liang X, Huang W, Lai KP, Zhou L. Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis. Front Nutr 2022;9:867692. [DOI: 10.3389/fnut.2022.867692] [Reference Citation Analysis]
82 Hu Y, Ye Z, She Y, Li L, Wu M, Qin K, Li Y, He H, Hu Z, Yang M, Lu F, Ye Q. Efficacy and Safety of Probiotics Combined With Traditional Chinese Medicine for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Front Pharmacol 2022;13:844961. [DOI: 10.3389/fphar.2022.844961] [Reference Citation Analysis]
83 D'Amico F, Peyrin-Biroulet L, Danese S. Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. J Clin Med 2020;9:E1536. [PMID: 32438763 DOI: 10.3390/jcm9051536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
84 Huang B, Wang L, Liu M, Wu X, Lu Q, Liu R. The underlying mechanism of A-type procyanidins from peanut skin on DSS-induced ulcerative colitis mice by regulating gut microbiota and metabolism. J Food Biochem 2022;:e14103. [PMID: 35218055 DOI: 10.1111/jfbc.14103] [Reference Citation Analysis]
85 Chen Y, Wu D, Sun L. Clinical Significance of High-Mobility Group Box 1 Protein (HMGB1) and Nod-Like Receptor Protein 3 (NLRP3) in Patients with Ulcerative Colitis. Med Sci Monit 2020;26:e919530. [PMID: 31901930 DOI: 10.12659/MSM.919530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Wang JH, D’arcy M, Barnes EL, Freedman ND, Engels EA, Song M. Associations of Inflammatory Bowel Disease and Subsequent Cancers in a Population-Based Study of Older Adults in the United States. JNCI Cancer Spectrum 2022;6:pkab096. [DOI: 10.1093/jncics/pkab096] [Reference Citation Analysis]
87 Nishikawa Y, Sato N, Tsukinaga S, Uchiyama K, Koido S, Ishikawa D, Ohkusa T. Long-term outcomes of antibiotic combination therapy for ulcerative colitis. Ther Adv Chronic Dis 2021;12:20406223211028790. [PMID: 34285790 DOI: 10.1177/20406223211028790] [Reference Citation Analysis]
88 Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00377-0. [PMID: 34856198 DOI: 10.1016/S2468-1253(21)00377-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Lubrano E, Luchetti MM, Benfaremo D, Mauro D, Ciccia F, Perrotta FM. Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. Expert Rev Clin Immunol 2021;17:1199-209. [PMID: 34622735 DOI: 10.1080/1744666X.2021.1991315] [Reference Citation Analysis]
90 Armuzzi A, DiBonaventura MD, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Quirk D, Salese L. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS One 2020;15:e0227914. [PMID: 31945774 DOI: 10.1371/journal.pone.0227914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
91 Pandey M, Choudhury H, D/O Segar Singh SK, Chetty Annan N, Bhattamisra SK, Gorain B, Mohd Amin MCI. Budesonide-Loaded Pectin/Polyacrylamide Hydrogel for Sustained Delivery: Fabrication, Characterization and In Vitro Release Kinetics. Molecules 2021;26:2704. [PMID: 34062995 DOI: 10.3390/molecules26092704] [Reference Citation Analysis]
92 Zhang S, Chen F, Wu J, Liu C, Yang G, Piao R, Geng B, Xu K, Liu P. Regional Gray Matter Volume Changes in Brains of Patients With Ulcerative Colitis. Inflamm Bowel Dis 2021:izab252. [PMID: 34734248 DOI: 10.1093/ibd/izab252] [Reference Citation Analysis]
93 Kantasiripitak W, Wang Z, Spriet I, Ferrante M, Dreesen E. Recent advancements in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert Rev Clin Pharmacol 2022. [PMID: 35034509 DOI: 10.1080/17512433.2021.2028619] [Reference Citation Analysis]
94 Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis 2019;13:1217-26. [PMID: 30879034 DOI: 10.1093/ecco-jcc/jjz038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
95 Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. J Clin Med 2021;10:5642. [PMID: 34884344 DOI: 10.3390/jcm10235642] [Reference Citation Analysis]
96 Labarile N, Ghosh S, Ng SC, Walters J, Iacucci M. Tests that now deserve to be more widely adopted in IBD clinical practice. Therap Adv Gastroenterol 2020;13:1756284820944088. [PMID: 32782481 DOI: 10.1177/1756284820944088] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Zhu F, Zheng J, Xu F, Xi Y, Chen J, Xu X. Resveratrol Alleviates Dextran Sulfate Sodium-Induced Acute Ulcerative Colitis in Mice by Mediating PI3K/Akt/VEGFA Pathway. Front Pharmacol 2021;12:693982. [PMID: 34497510 DOI: 10.3389/fphar.2021.693982] [Reference Citation Analysis]
98 Csekő K, Beckers B, Keszthelyi D, Helyes Z. Role of TRPV1 and TRPA1 Ion Channels in Inflammatory Bowel Diseases: Potential Therapeutic Targets? Pharmaceuticals (Basel) 2019;12:E48. [PMID: 30935063 DOI: 10.3390/ph12020048] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
99 Xu X, Zhang J, Chen L, Sun Y, Qing D, Xin X, Yan C. Alhagi pseudalhagi Extract Exerts Protective Effects Against Intestinal Inflammation in Ulcerative Colitis by Affecting TLR4-Dependent NF-κB Signaling Pathways. Front Pharmacol 2021;12:764602. [PMID: 34803708 DOI: 10.3389/fphar.2021.764602] [Reference Citation Analysis]
100 Deng M, Hu J, Tong R, Guo H, Li X, Liu Y. miR-452-5p regulates the responsiveness of intestinal epithelial cells in inflammatory bowel disease through Mcl-1. Exp Ther Med 2021;22:813. [PMID: 34131436 DOI: 10.3892/etm.2021.10245] [Reference Citation Analysis]
101 Bing X, Xuelei L, Wanwei D, Linlang L, Keyan C. EGCG Maintains Th1/Th2 Balance and Mitigates Ulcerative Colitis Induced by Dextran Sulfate Sodium through TLR4/MyD88/NF-κB Signaling Pathway in Rats. Can J Gastroenterol Hepatol 2017;2017:3057268. [PMID: 29404307 DOI: 10.1155/2017/3057268] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
102 Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S. Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. Inflamm Bowel Dis 2020;26:1429-35. [PMID: 31748806 DOI: 10.1093/ibd/izz276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol 2019;85:2244-54. [PMID: 31269287 DOI: 10.1111/bcp.14051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
104 Wu X, Chen H, Gao X, Gao H, He Q, Li G, Yao J, Liu Z. Natural Herbal Remedy Wumei Decoction Ameliorates Intestinal Mucosal Inflammation by Inhibiting Th1/Th17 Cell Differentiation and Maintaining Microbial Homeostasis. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab348] [Reference Citation Analysis]
105 Jiao C, Zhang Q, Yang M, Ma J, Zhao X, Tang N, Dai M, Li Q, Jiang Z, Huang X, Zhang H, Sun L. Shenling Baizhu San ameliorates ulcerative colitis by regulating the gut microbiota and its tryptophan metabolites: A complementary medicine to mesalamine. J Ethnopharmacol 2022;:115145. [PMID: 35219821 DOI: 10.1016/j.jep.2022.115145] [Reference Citation Analysis]
106 Yusuf F, Kamarlis RK, Muhsin M. Ulcerative Colitis in Hemophilia A Patient: Case Report. Mater Sociomed 2021;33:75-7. [PMID: 34012356 DOI: 10.5455/msm.2021.33.75-77] [Reference Citation Analysis]
107 Joher N, Gosset C, Guerrot D, Pillebout E, Hummel A, Boffa JJ, Faguer S, Rabant M, Higgins S, Moktefi A, Delmas Y, Karras A, Lapidus N, Amiot A, Audard V, El Karoui K. IgA nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. Nephrol Dial Transplant 2021:gfaa378. [PMID: 33416845 DOI: 10.1093/ndt/gfaa378] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Hu H, Lei Y, Zhang W, Xiong P, Song L, Luo X, Jia B, Zhang F. Anti-inflammatory activity and safety of compound glycyrrhizin in ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials. Journal of Functional Foods 2022;91:105004. [DOI: 10.1016/j.jff.2022.105004] [Reference Citation Analysis]
109 Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World J Gastroenterol 2021; 27(22): 3109-3120 [PMID: 34168412 DOI: 10.3748/wjg.v27.i22.3109] [Reference Citation Analysis]
110 Acovic A, Simovic Markovic B, Gazdic M, Arsenijevic A, Jovicic N, Gajovic N, Jovanovic M, Zdravkovic N, Kanjevac T, Harrell CR, Fellabaum C, Dolicanin Z, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. Therap Adv Gastroenterol. 2018;11:1756284818793558. [PMID: 30159037 DOI: 10.1177/1756284818793558] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
111 Zhou Y, Hu Z, Ye F, Guo T, Luo Y, Zhou W, Qin D, Tang Y, Cao F, Luo F, Lin Q. Mogroside V exerts anti-inflammatory effect via MAPK-NF-κB/AP-1 and AMPK-PI3K/Akt/mTOR pathways in ulcerative colitis. Journal of Functional Foods 2021;87:104807. [DOI: 10.1016/j.jff.2021.104807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Chen YX, Zhang XQ, Yu CG, Huang SL, Xie Y, Dou XT, Liu WJ, Zou XP. Artesunate exerts protective effects against ulcerative colitis via suppressing Toll‑like receptor 4 and its downstream nuclear factor‑κB signaling pathways. Mol Med Rep 2019;20:1321-32. [PMID: 31173225 DOI: 10.3892/mmr.2019.10345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
113 Levy AN, Allegretti JR. Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease. Therap Adv Gastroenterol 2019;12:1756284819836893. [PMID: 30906424 DOI: 10.1177/1756284819836893] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
114 Lin R, Chen H, Shu W, Sun M, Fang L, Shi Y, Pang Z, Wu W, Liu Z. Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease. J Transl Med 2018;16:359. [PMID: 30558634 DOI: 10.1186/s12967-018-1723-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
115 Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford) 2021;60:ii45-51. [PMID: 33950226 DOI: 10.1093/rheumatology/keaa896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Chen Z, Lu Y, Wu J, Zhang H. Clinical significance of blood platelets and mean platelet volume in patients with ulcerative colitis. J Int Med Res 2021;49:3000605211009715. [PMID: 33884913 DOI: 10.1177/03000605211009715] [Reference Citation Analysis]
117 Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:1760-1768.e1. [PMID: 31546056 DOI: 10.1016/j.cgh.2019.09.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
118 Battistini C, Ballan R, Herkenhoff ME, Saad SMI, Sun J. Vitamin D Modulates Intestinal Microbiota in Inflammatory Bowel Diseases. Int J Mol Sci 2020;22:E362. [PMID: 33396382 DOI: 10.3390/ijms22010362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
119 Hasan B, Ur Rahman A. Ulcerative Colitis and Diverticulitis Are Possibly Connected to the Same Hub. Inflamm Bowel Dis 2022:izac057. [PMID: 35460402 DOI: 10.1093/ibd/izac057] [Reference Citation Analysis]
120 Liu L, Liang L, Yang C, Zhou Y, Chen Y. Extracellular vesicles of Fusobacterium nucleatum compromise intestinal barrier through targeting RIPK1-mediated cell death pathway. Gut Microbes 2021;13:1-20. [PMID: 33769187 DOI: 10.1080/19490976.2021.1902718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Cui HR, Zhang JY, Cheng XH, Zheng JX, Zhang Q, Zheng R, You LZ, Han DR, Shang HC. Immunometabolism at the service of traditional Chinese medicine. Pharmacol Res 2022;:106081. [PMID: 35033650 DOI: 10.1016/j.phrs.2022.106081] [Reference Citation Analysis]
122 Slevin SM, Garner LC, Lahiff C, Tan M, Wang LM, Ferry H, Greenaway B, Lynch K, Geremia A, Hughes S, Leavens K, Krull D, Marks DJB, Nevin K, Page K, Srinivasan N, Tarzi R, Klenerman P, Travis S, Arancibia-Cárcamo CV, Keshav S. Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. J Crohns Colitis 2020;14:1446-61. [PMID: 32179884 DOI: 10.1093/ecco-jcc/jjaa054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
123 Lv Q, Shi C, Qiao S, Cao N, Guan C, Dai Y, Wei Z. Alpinetin exerts anti-colitis efficacy by activating AhR, regulating miR-302/DNMT-1/CREB signals, and therefore promoting Treg differentiation. Cell Death Dis 2018;9:890. [PMID: 30166541 DOI: 10.1038/s41419-018-0814-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
124 Gwiggner M, Martinez-Nunez RT, Whiteoak SR, Bondanese VP, Claridge A, Collins JE, Cummings JRF, Sanchez-Elsner T. MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor α-1. Genes (Basel) 2018;9:E85. [PMID: 29438285 DOI: 10.3390/genes9020085] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
125 Hu JE, Weiß F, Bojarski C, Branchi F, Schulzke JD, Fromm M, Krug SM. Expression of tricellular tight junction proteins and the paracellular macromolecule barrier are recovered in remission of ulcerative colitis. BMC Gastroenterol 2021;21:141. [PMID: 33789594 DOI: 10.1186/s12876-021-01723-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Virili C, Stramazzo I, Santaguida MG, Bruno G, Brusca N, Capriello S, Cellini M, Severi C, Gargano L, Centanni M. Ulcerative Colitis as a Novel Cause of Increased Need for Levothyroxine. Front Endocrinol (Lausanne) 2019;10:233. [PMID: 31040825 DOI: 10.3389/fendo.2019.00233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
127 Qi Q, Liu Y, Lv S, Wu H, Zhang L, Cao Z, Liu H, Wang X, Wu L. Gut microbiome alterations in colitis rats after moxibustion at bilateral Tianshu acupoints. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02115-1] [Reference Citation Analysis]
128 Xie Q, Li H, Ma R, Ren M, Li Y, Li J, Chen H, Chen Z, Gong D, Wang J. Effect of Coptis chinensis franch and Magnolia officinalis on intestinal flora and intestinal barrier in a TNBS-induced ulcerative colitis rats model. Phytomedicine 2022;97:153927. [PMID: 35030387 DOI: 10.1016/j.phymed.2022.153927] [Reference Citation Analysis]
129 Wen T, Faye AS, Lee KE, Friedman AM, Wright JD, Lebwohl B, Colombel JF. Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months. Dig Dis Sci 2021. [PMID: 33932199 DOI: 10.1007/s10620-021-06999-z] [Reference Citation Analysis]
130 Sun Z, Li J, Wang W, Liu Y, Liu J, Jiang H, Lu Q, Ding P, Shi R, Zhao X, Yuan W, Tan X, Shi X, Xing Y, Mao T. Qingchang Wenzhong Decoction Accelerates Intestinal Mucosal Healing Through Modulation of Dysregulated Gut Microbiome, Intestinal Barrier and Immune Responses in Mice. Front Pharmacol 2021;12:738152. [PMID: 34557102 DOI: 10.3389/fphar.2021.738152] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Wang X, Gao Y, Wang L, Yang D, Bu W, Gou L, Huang J, Duan X, Pan Y, Cao S, Gao Z, Cheng C, Feng Z, Xie J, Yao R. Troxerutin Improves Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. J Agric Food Chem 2021;69:2729-44. [PMID: 33621077 DOI: 10.1021/acs.jafc.0c06755] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
132 Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol 2022;7:28-37. [PMID: 34798037 DOI: 10.1016/S2468-1253(21)00295-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
133 Zhou QY, Zhou WX, Sun XY, Wu B, Zheng WY, Li Y, Qian JM. Autoimmune enteropathy and primary biliary cholangitis after proctocolectomy for ulcerative colitis: A case report and review of the literature. World J Gastroenterol 2021; 27(29): 4929-4938 [PMID: 34447236 DOI: 10.3748/wjg.v27.i29.4929] [Reference Citation Analysis]
134 Yan Z, He F, Xiao F, He H, Li D, Cong L, Lin L, Zhu H, Wu Y, Yan R, Li X, Shan H. A semi-tryptic peptide centric metaproteomic mining approach and its potential utility in capturing signatures of gut microbial proteolysis. Microbiome 2021;9:12. [PMID: 33436102 DOI: 10.1186/s40168-020-00967-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Ciccocioppo R, Mengoli C, Betti E, Comolli G, Cassaniti I, Piralla A, Kruzliak P, Caprnda M, Pozzi L, Corazza GR, Di Sabatino A, Baldanti F. Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. Clin Exp Med 2021;21:379-88. [PMID: 33772380 DOI: 10.1007/s10238-021-00702-2] [Reference Citation Analysis]
136 Lin Y, Qi X, Liu H, Xue K, Xu S, Tian Z. The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations. Cancer Cell Int 2020;20:154. [PMID: 32410882 DOI: 10.1186/s12935-020-01233-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
137 Bertani L, Tricò D, Zanzi F, Baiano Svizzero G, Coppini F, de Bortoli N, Bellini M, Antonioli L, Blandizzi C, Marchi S. Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis. Nutrients 2021;13:608. [PMID: 33673371 DOI: 10.3390/nu13020608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
138 Yang L, Bian Y, Li Z, Yan Y, Li J, Li W, Zeng L. Identification of potential biomarkers and pathways in ulcerative colitis with combined public mRNA and miRNA expression microarray data analysis. J Gastrointest Oncol 2019;10:847-58. [PMID: 31602322 DOI: 10.21037/jgo.2019.06.06] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
139 Kurt S, Caron B, Gouynou C, Netter P, Vaizey CJ, Wexner SD, Danese S, Baumann C, Peyrin-Biroulet L. Faecal incontinence in inflammatory bowel disease: The Nancy experience. Dig Liver Dis 2022:S1590-8658(22)00136-0. [PMID: 35123908 DOI: 10.1016/j.dld.2022.01.125] [Reference Citation Analysis]
140 Vollenberg R, Tepasse P, Kühn JE, Hennies M, Strauss M, Rennebaum F, Schomacher T, Boeckel G, Lorentzen E, Bokemeyer A, Nowacki TM. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines 2022;10:171. [DOI: 10.3390/biomedicines10010171] [Reference Citation Analysis]
141 Chao L, Li Z, Zhou J, Chen W, Li Y, Lv W, Guo A, Qu Q, Guo S. Shen-Ling-Bai-Zhu-San Improves Dextran Sodium Sulfate-Induced Colitis by Inhibiting Caspase-1/Caspase-11-Mediated Pyroptosis. Front Pharmacol 2020;11:814. [PMID: 32547403 DOI: 10.3389/fphar.2020.00814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
142 Zhang J, Xu X, Li N, Cao L, Sun Y, Wang J, He S, Si J, Qing D. Licoflavone B, an isoprene flavonoid derived from licorice residue, relieves dextran sodium sulfate-induced ulcerative colitis by rebuilding the gut barrier and regulating intestinal microflora. Eur J Pharmacol 2021;:174730. [PMID: 34968462 DOI: 10.1016/j.ejphar.2021.174730] [Reference Citation Analysis]
143 Shi B, Liu S, Huang A, Zhou M, Sun B, Cao H, Shan J, Sun B, Lin J. Revealing the Mechanism of Friedelin in the Treatment of Ulcerative Colitis Based on Network Pharmacology and Experimental Verification. Evid Based Complement Alternat Med 2021;2021:4451779. [PMID: 34765000 DOI: 10.1155/2021/4451779] [Reference Citation Analysis]
144 Zhao N, Yang FE, Zhao CY, Lv SW, Wang J, Liu JM, Wang S. Construction of pH-Dependent Nanozymes with Oxygen Vacancies as the High-Efficient Reactive Oxygen Species Scavenger for Oral-Administrated Anti-Inflammatory Therapy. Adv Healthc Mater 2021;10:e2101618. [PMID: 34569192 DOI: 10.1002/adhm.202101618] [Reference Citation Analysis]
145 Zakerska-Banaszak O, Tomczak H, Gabryel M, Baturo A, Wolko L, Michalak M, Malinska N, Mankowska-Wierzbicka D, Eder P, Dobrowolska A, Slomski R, Skrzypczak-Zielinska M. Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study. Sci Rep 2021;11:2166. [PMID: 33495479 DOI: 10.1038/s41598-021-81628-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
146 Youssef ME, Abd El-Fattah EE, Abdelhamid AM, Eissa H, El-Ahwany E, Amin NA, Hetta HF, Mahmoud MH, Batiha GE, Gobba N, Ahmed Gaafar AG, Saber S. Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis. Front Pharmacol 2021;12:719984. [PMID: 34489707 DOI: 10.3389/fphar.2021.719984] [Reference Citation Analysis]
147 Wagatsuma K, Nakase H. Contradictory Effects of NLRP3 Inflammasome Regulatory Mechanisms in Colitis. Int J Mol Sci 2020;21:E8145. [PMID: 33143375 DOI: 10.3390/ijms21218145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
148 Skolmowska D, Głąbska D, Guzek D, Lech G. Association between Dietary Isoflavone Intake and Ulcerative Colitis Symptoms in Polish Caucasian Individuals. Nutrients 2019;11:E1936. [PMID: 31426486 DOI: 10.3390/nu11081936] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
149 He L, Wen S, Zhong Z, Weng S, Jiang Q, Mi H, Liu F. The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis. Front Pharmacol 2021;12:625543. [PMID: 34093178 DOI: 10.3389/fphar.2021.625543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Mennillo E, Yang X, Paszek M, Auwerx J, Benner C, Chen S. NCoR1 Protects Mice From Dextran Sodium Sulfate-Induced Colitis by Guarding Colonic Crypt Cells From Luminal Insult. Cell Mol Gastroenterol Hepatol 2020;10:133-47. [PMID: 32044398 DOI: 10.1016/j.jcmgh.2020.01.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
151 Miao Z, Chen L, Feng H, Gu M, Yan J, Xu Y, Ye B. Baitouweng Decoction Ameliorates Ulcerative Colitis in Mice Partially Attributed to Regulating Th17/Treg Balance and Restoring Intestinal Epithelial Barrier. Front Pharmacol 2020;11:531117. [PMID: 33597862 DOI: 10.3389/fphar.2020.531117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Sah J, Teeple A, Muser E, Gutierrez C, Dassopoulos T. Treatment persistence and maintenance dose titration among ulcerative colitis on biologics: a pooled study of three United States claim databases. Curr Med Res Opin 2022;:1-25. [PMID: 35475385 DOI: 10.1080/03007995.2022.2071041] [Reference Citation Analysis]
153 Tepler A, Narula N, Peek RM Jr, Patel A, Edelson C, Colombel JF, Shah SC. Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:121-31. [PMID: 31165513 DOI: 10.1111/apt.15306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
154 Schniers A, Goll R, Pasing Y, Sørbye SW, Florholmen J, Hansen T. Ulcerative colitis: functional analysis of the in-depth proteome. Clin Proteomics 2019;16:4. [PMID: 30718987 DOI: 10.1186/s12014-019-9224-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
155 Liu J, Yu L, Mo N, Lan H, Zhang Y, Liu X, Wu Q. Supercritical Fluid Extract of Angelica sinensis and Zingiber officinale Roscoe Ameliorates TNBS-Induced Colitis in Rats. Int J Mol Sci 2019;20:E3816. [PMID: 31387229 DOI: 10.3390/ijms20153816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
156 Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol 2020;55:169-80. [PMID: 31529220 DOI: 10.1007/s00535-019-01625-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
157 Schiff ER, Frampton M, Semplici F, Bloom SL, McCartney SA, Vega R, Lovat LB, Wood E, Hart AL, Crespi D, Furman MA, Mann S, Murray CD, Segal AW, Levine AP. A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population. Dig Dis Sci 2018;63:3049-57. [PMID: 30178286 DOI: 10.1007/s10620-018-5219-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
158 Faramarzpour A, Tehrani AA, Tamaddonfard E, Imani M. The effects of crocin, mesalazine and their combination in the acetic acid-induced colitis in rats. Vet Res Forum 2019;10:227-34. [PMID: 31737232 DOI: 10.30466/vrf.2019.35900] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
159 Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:424-431.e7. [PMID: 31108227 DOI: 10.1016/j.cgh.2019.05.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
160 Markovic M, Dahan A, Keinan S, Kurnikov I, Aponick A, Zimmermann EM, Ben-Shabat S. Phospholipid-Based Prodrugs for Colon-Targeted Drug Delivery: Experimental Study and In-Silico Simulations. Pharmaceutics 2019;11:E186. [PMID: 30995772 DOI: 10.3390/pharmaceutics11040186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
161 Mo A, Nagpal S, Gettler K, Haritunians T, Giri M, Haberman Y, Karns R, Prince J, Arafat D, Hsu NY, Chuang LS, Argmann C, Kasarskis A, Suarez-Farinas M, Gotman N, Mengesha E, Venkateswaran S, Rufo PA, Baker SS, Sauer CG, Markowitz J, Pfefferkorn MD, Rosh JR, Boyle BM, Mack DR, Baldassano RN, Shah S, LeLeiko NS, Heyman MB, Griffiths AM, Patel AS, Noe JD, Davis Thomas S, Aronow BJ, Walters TD, McGovern DPB, Hyams JS, Kugathasan S, Cho JH, Denson LA, Gibson G. Stratification of risk of progression to colectomy in ulcerative colitis via measured and predicted gene expression. Am J Hum Genet 2021;108:1765-79. [PMID: 34450030 DOI: 10.1016/j.ajhg.2021.07.013] [Reference Citation Analysis]
162 Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2018;24:2258-2265. [PMID: 29850873 DOI: 10.1093/ibd/izy131] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 29.0] [Reference Citation Analysis]
163 Shen Z, Zheng K, Zou J, Gu P, Xing J, Zhang L, Zhu L, Shen H. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. Trials 2021;22:55. [PMID: 33441157 DOI: 10.1186/s13063-020-05012-8] [Reference Citation Analysis]
164 Hua G, Zein N, Daubeuf F, Chambon P. Glucocorticoid receptor modulators CpdX and CpdX-D3 exhibit the same in vivo antiinflammatory activities as synthetic glucocorticoids. Proc Natl Acad Sci U S A 2019;116:14191-9. [PMID: 31227605 DOI: 10.1073/pnas.1908258116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
165 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Reference Citation Analysis]
166 Liu S, Li Q, Liu F, Cao H, Liu J, Shan J, Dan W, Yuan J, Lin J. Uncovering the Mechanism of Curcuma in the Treatment of Ulcerative Colitis Based on Network Pharmacology, Molecular Docking Technology, and Experiment Verification. Evid Based Complement Alternat Med 2021;2021:6629761. [PMID: 34221084 DOI: 10.1155/2021/6629761] [Reference Citation Analysis]
167 Voss J, Schneider CV, Kleinjans M, Bruns T, Trautwein C, Strnad P. Hepatobiliary phenotype of individuals with chronic intestinal disorders. Sci Rep 2021;11:19954. [PMID: 34620902 DOI: 10.1038/s41598-021-98843-7] [Reference Citation Analysis]
168 Liu J, Zhao W, Li C, Wu T, Han L, Hu Z, Li X, Zhou J, Chen X. Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders. Int J Mol Sci 2021;23:416. [PMID: 35008842 DOI: 10.3390/ijms23010416] [Reference Citation Analysis]
169 Hoffmann P, Globig AM, Thomann AK, Grigorian M, Krisam J, Hasselblatt P, Reindl W, Gauss A. Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study. J Clin Med 2020;9:E2177. [PMID: 32664204 DOI: 10.3390/jcm9072177] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
170 Gu D, Nan Q, Miao Y, Yang H, Li M, Ye Y, Miao J. KT2 alleviates ulcerative colitis by reducing Th17 cell differentiation through the miR-302c-5p/STAT3 axis. Eur J Cell Biol 2022;101:151223. [PMID: 35405463 DOI: 10.1016/j.ejcb.2022.151223] [Reference Citation Analysis]
171 Yokoyama M, Kimura MY, Ito T, Hayashizaki K, Endo Y, Wang Y, Yagi R, Nakagawa T, Kato N, Matsubara H, Nakayama T. Myosin Light Chain 9/12 Regulates the Pathogenesis of Inflammatory Bowel Disease. Front Immunol 2020;11:594297. [PMID: 33584659 DOI: 10.3389/fimmu.2020.594297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Honjo H, Watanabe T, Kamata K, Minaga K, Kudo M. RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases. Front Pharmacol 2021;12:650403. [PMID: 33935757 DOI: 10.3389/fphar.2021.650403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
173 Marafini I, Salvatori S, Rocchetti I, Alfieri N, Scarozza P, Calabrese E, Biancone L, Monteleone G. Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis. J Clin Med 2021;10:1192. [PMID: 33809208 DOI: 10.3390/jcm10061192] [Reference Citation Analysis]
174 Sharma S, Gioia L, Abe B, Holt M, Costanzo A, Kain L, Su A, Teyton L. Using single cell analysis for translational studies in immune mediated diseases: Opportunities and challenges. Mol Immunol 2018;103:191-9. [PMID: 30300798 DOI: 10.1016/j.molimm.2018.09.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
175 Park SK, Kim HN, Choi CH, Im JP, Cha JM, Eun CS, Kim TO, Kang SB, Bang KB, Kim HG, Jung Y, Yoon H, Han DS, Lee CW, Ahn K, Kim HL, Park DI. Differentially Abundant Bacterial Taxa Associated with Prognostic Variables of Crohn's Disease: Results from the IMPACT Study. J Clin Med 2020;9:E1748. [PMID: 32516912 DOI: 10.3390/jcm9061748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
176 Lee JS, Wang RX, Goldberg MS, Clifford GP, Kao DJ, Colgan SP. Microbiota-Sourced Purines Support Wound Healing and Mucous Barrier Function. iScience 2020;23:101226. [PMID: 32554188 DOI: 10.1016/j.isci.2020.101226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
177 Chen S, Liu H, Li Z, Tang J, Huang B, Zhi F, Zhao X. Epithelial PBLD attenuates intestinal inflammatory response and improves intestinal barrier function by inhibiting NF-κB signaling. Cell Death Dis 2021;12:563. [PMID: 34059646 DOI: 10.1038/s41419-021-03843-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Huang C, Xu J, Li J, He S, Xu H, Ren X, Singh V, Wu L, Zhang J. Hydrogen peroxide responsive covalent cyclodextrin framework for targeted therapy of inflammatory bowel disease. Carbohydrate Polymers 2022;285:119252. [DOI: 10.1016/j.carbpol.2022.119252] [Reference Citation Analysis]
179 Othman MO, Harb D, Barkin JA. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract. 2018;72. [PMID: 29405509 DOI: 10.1111/ijcp.13066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
180 Saez A, Gomez-Bris R, Herrero-Fernandez B, Mingorance C, Rius C, Gonzalez-Granado JM. Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease. Int J Mol Sci 2021;22:7618. [PMID: 34299236 DOI: 10.3390/ijms22147618] [Reference Citation Analysis]
181 Wang HG, Zhang MN, Wen X, He L, Zhang MH, Zhang JL, Yang XZ. Cepharanthine ameliorates dextran sulphate sodium-induced colitis through modulating gut microbiota. Microb Biotechnol 2022. [PMID: 35439340 DOI: 10.1111/1751-7915.14059] [Reference Citation Analysis]
182 Zou Y, Liu S, Wu J, Sun Z. Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature. World J Surg Oncol 2021;19:332. [PMID: 34809643 DOI: 10.1186/s12957-021-02443-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Chapuy L, Bsat M, Rubio M, Sarkizova S, Therrien A, Bouin M, Orlicka K, Weber A, Soucy G, Villani AC, Sarfati M. IL-12 and Mucosal CD14+ Monocyte-Like Cells Induce IL-8 in Colonic Memory CD4+ T Cells of Patients With Ulcerative Colitis but not Crohn's Disease. J Crohns Colitis 2020;14:79-95. [PMID: 31206576 DOI: 10.1093/ecco-jcc/jjz115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
184 Shi H, Wang D, Chen W, Li Y, Si G, Yang T, Alhumaydhi FA. Quality of Evidence Supporting the Role of Supplement Curcumin for the Treatment of Ulcerative Colitis: An Overview of Systematic Reviews. Gastroenterology Research and Practice 2022;2022:1-13. [DOI: 10.1155/2022/3967935] [Reference Citation Analysis]
185 Olbei M, Thomas JP, Hautefort I, Treveil A, Bohar B, Madgwick M, Gul L, Csabai L, Modos D, Korcsmaros T. CytokineLink: A Cytokine Communication Map to Analyse Immune Responses-Case Studies in Inflammatory Bowel Disease and COVID-19. Cells 2021;10:2242. [PMID: 34571891 DOI: 10.3390/cells10092242] [Reference Citation Analysis]
186 Mikkelsen G, Lillebo B, Faxvaag A. Disease-associated reference intervals for twenty laboratory tests in patients with rheumatoid arthritis, Crohn's disease or ulcerative colitis. Pract Lab Med 2021;25:e00225. [PMID: 34095413 DOI: 10.1016/j.plabm.2021.e00225] [Reference Citation Analysis]
187 Merkley SD, Chock CJ, Yang XO, Harris J, Castillo EF. Modulating T Cell Responses via Autophagy: The Intrinsic Influence Controlling the Function of Both Antigen-Presenting Cells and T Cells. Front Immunol. 2018;9:2914. [PMID: 30619278 DOI: 10.3389/fimmu.2018.02914] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
188 Rubin DT, Hart A, Panaccione R, Armuzzi A, Suvanto U, Deuring JJ, Woolcott J, Cappelleri JC, Steinberg K, Wingate L, Schreiber S. Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. Inflamm Bowel Dis 2021;27:1096-106. [PMID: 33057598 DOI: 10.1093/ibd/izaa257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
189 Zhang C, Li J, Xiao M, Wang D, Qu Y, Zou L, Zheng C, Zhang J. Oral colon-targeted mucoadhesive micelles with enzyme-responsive controlled release of curcumin for ulcerative colitis therapy. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.110] [Reference Citation Analysis]
190 Farag MA, Gad MZ. Omega-9 fatty acids: potential roles in inflammation and cancer management. J Genet Eng Biotechnol 2022;20:48. [PMID: 35294666 DOI: 10.1186/s43141-022-00329-0] [Reference Citation Analysis]
191 Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
192 Shimodaira Y, Watanabe K, Fukuda S, Watanabe N, Koizumi S, Matsuhashi T, Onochi K, Iijima K. Limited endoscopic mucosal inflammation on equivalent to Mayo endoscopic subscore of 0 unaffect clinical relapse of ulcerative colitis. Scand J Gastroenterol 2021;:1-4. [PMID: 34663142 DOI: 10.1080/00365521.2021.1991467] [Reference Citation Analysis]
193 Xie Y, Chen J, Wu B, He T, Xie L, Liu Z. Dock2 affects the host susceptibility to Citrobacter rodentium infection through regulating gut microbiota. Gut Pathog 2021;13:52. [PMID: 34391464 DOI: 10.1186/s13099-021-00449-x] [Reference Citation Analysis]
194 Wu T, Yang X, Xu B, Zhu H, Guo J, Zhou Y, Liang G, Sun H. Using Network Pharmacology and Molecular Docking Technology to Explore the Mechanism of Modified Pulsatilla Decoction in the Treatment of Ulcerative Colitis. Natural Product Communications 2022;17:1934578X2210988. [DOI: 10.1177/1934578x221098850] [Reference Citation Analysis]
195 Leber A, Hontecillas R, Zoccoli-Rodriguez V, Bienert C, Chauhan J, Bassaganya-Riera J. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol 2019;203:3407-15. [PMID: 31694910 DOI: 10.4049/jimmunol.1900364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
196 Akintimehin AO, O'Neill RS, Ring C, Raftery T, Hussey S. Outcomes of a National Cohort of Children with Acute Severe Ulcerative Colitis. Front Pediatr 2018;6:48. [PMID: 29568735 DOI: 10.3389/fped.2018.00048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
197 D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis 2021:jjab206. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Reference Citation Analysis]
198 Cushing KC, Tan W, Alpers DH, Deshpande V, Ananthakrishnan AN. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther 2020;51:347-55. [PMID: 31696961 DOI: 10.1111/apt.15568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
199 Blander JM. On cell death in the intestinal epithelium and its impact on gut homeostasis. Curr Opin Gastroenterol 2018;34:413-9. [PMID: 30169459 DOI: 10.1097/MOG.0000000000000481] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
200 Xu X, Lin S, Yang Y, Gong X, Tong J, Li K, Li Y. Histological and ultrastructural changes of the colon in dextran sodium sulfate-induced mouse colitis. Exp Ther Med 2020;20:1987-94. [PMID: 32782508 DOI: 10.3892/etm.2020.8946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
201 Li W, Zhang L, Xu Q, Yang W, Zhao J, Ren Y, Yu Z, Ma L. Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid. Nutrients 2022;14:1069. [DOI: 10.3390/nu14051069] [Reference Citation Analysis]
202 Pak S, Hwang SW, Shim IK, Bae SM, Ryu YM, Kim HB, Do EJ, Son HN, Choi EJ, Park SH, Kim SY, Park SH, Ye BD, Yang SK, Kanai N, Maeda M, Okano T, Yang DH, Byeon JS, Myung SJ. Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats. Sci Rep 2018;8:11314. [PMID: 30054522 DOI: 10.1038/s41598-018-29617-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
203 Ji E, Wang T, Xu J, Fan J, Zhang Y, Guan Y, Yang H, Wei J, Zhang G, Huang L. Systematic Investigation of the Efficacy of Sinitang Decoction Against Ulcerative Colitis. Front Pharmacol 2020;11:1337. [PMID: 32982747 DOI: 10.3389/fphar.2020.01337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients. medRxiv 2021:2021. [PMID: 33501455 DOI: 10.1101/2021.01.15.21249889] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Monteleone G, Franzè E, Troncone E, Maresca C, Marafini I. Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut. Front Immunol 2022;13:873332. [DOI: 10.3389/fimmu.2022.873332] [Reference Citation Analysis]
206 Xu J, Chen N, Wu Z, Song Y, Zhang Y, Wu N, Zhang F, Ren X, Liu Y. 5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. Front Microbiol 2018;9:1274. [PMID: 29951050 DOI: 10.3389/fmicb.2018.01274] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
207 Chen R, Tie Y, Lu J, Li L, Zeng Z, Chen M, Zhang S. Tripartite motif family proteins in inflammatory bowel disease: Mechanisms and potential for interventions. Cell Prolif 2022;:e13222. [PMID: 35373402 DOI: 10.1111/cpr.13222] [Reference Citation Analysis]
208 Lu X, Jing Y, Zhang N, Cao Y. Eurotium cristatum, a Probiotic Fungus from Fuzhuan Brick Tea, and Its Polysaccharides Ameliorated DSS-Induced Ulcerative Colitis in Mice by Modulating the Gut Microbiota. J Agric Food Chem 2022. [PMID: 35201766 DOI: 10.1021/acs.jafc.1c08301] [Reference Citation Analysis]
209 Ma L, Pang X, Ji G, Ma X, Li J, Chang Y, Ma C. Application of the neutrophil to lymphocyte ratio in the diagnosis and activity determination of ulcerative colitis: A meta-analysis and systematic review. Medicine (Baltimore) 2021;100:e27551. [PMID: 34678891 DOI: 10.1097/MD.0000000000027551] [Reference Citation Analysis]
210 Yun X, Fang Y, Lv C, Qiao S, Tao Y, Dai Y, Xia Y. Inhibition of the activation of γδT17 cells through PPARγ-PTEN/Akt/GSK3β/NFAT pathway contributes to the anti-colitis effect of madecassic acid. Cell Death Dis 2020;11:752. [PMID: 32929062 DOI: 10.1038/s41419-020-02969-x] [Reference Citation Analysis]
211 Viscido A, Capannolo A, Petroni R, Stefanelli G, Zerboni G, De Martinis M, Necozione S, Penco M, Frieri G, Latella G, Romano S. Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases. Medicina (Kaunas) 2020;56:E382. [PMID: 32751480 DOI: 10.3390/medicina56080382] [Reference Citation Analysis]
212 Ito A, Murasugi S, Omori T, Nakamura S, Tokushige K. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. BMC Gastroenterol 2020;20:203. [PMID: 32590945 DOI: 10.1186/s12876-020-01317-9] [Reference Citation Analysis]
213 Pan HH, Zhou XX, Ma YY, Pan WS, Zhao F, Yu MS, Liu JQ. Resveratrol alleviates intestinal mucosal barrier dysfunction in dextran sulfate sodium-induced colitis mice by enhancing autophagy. World J Gastroenterol 2020; 26(33): 4945-4959 [PMID: 32952341 DOI: 10.3748/wjg.v26.i33.4945] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
214 Zhang XY, Dong HC, Wang WF, Zhang Y. Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis. World J Gastroenterol 2022; 28(16): 1705-1717 [DOI: 10.3748/wjg.v28.i16.1705] [Reference Citation Analysis]
215 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Chen X, Li X, Sun-Waterhouse D, Zhu B, You L, Hileuskaya K. Polysaccharides from Sargassum fusiforme after UV/H2O2 degradation effectively ameliorate dextran sulfate sodium-induced colitis. Food Funct 2021;12:11747-59. [PMID: 34806724 DOI: 10.1039/d1fo02708e] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Nascimento RPD, Machado APDF, Lima VS, Moya AMTM, Reguengo LM, Bogusz Junior S, Leal RF, Cao-Ngoc P, Rossi JC, Leclercq L, Cottet H, Cazarin CBB, Marostica Junior MR. Chemoprevention with a tea from hawthorn (Crataegus oxyacantha) leaves and flowers attenuates colitis in rats by reducing inflammation and oxidative stress. Food Chem X 2021;12:100139. [PMID: 34712949 DOI: 10.1016/j.fochx.2021.100139] [Reference Citation Analysis]
218 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
219 Takahara M, Hiraoka S, Ohmori M, Takeuchi K, Takei K, Yasutomi E, Igawa S, Yamamoto S, Yamasaki Y, Inokuchi T, Kinugasa H, Harada K, Ohnishi H, Okada H. The Colon Wall Thickness Measured Using Transabdominal Ultrasonography is Useful for Detecting Mucosal Inflammation in Ulcerative Colitis. Intern Med . [DOI: 10.2169/internalmedicine.8827-21] [Reference Citation Analysis]
220 Li H, Fan C, Lu H, Feng C, He P, Yang X, Xiang C, Zuo J, Tang W. Protective role of berberine on ulcerative colitis through modulating enteric glial cells-intestinal epithelial cells-immune cells interactions. Acta Pharm Sin B 2020;10:447-61. [PMID: 32140391 DOI: 10.1016/j.apsb.2019.08.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
221 Tang ML, Li H, Ning JF, Shen X, Sun X. Discovery of First-in-Class TAK1-MKK3 Protein-Protein Interaction (PPI) Inhibitor (R)-STU104 for the Treatment of Ulcerative Colitis through Modulating TNF-α Production. J Med Chem 2022. [PMID: 35442672 DOI: 10.1021/acs.jmedchem.1c02198] [Reference Citation Analysis]
222 Park J, Kang SJ, Yoon H, Park J, Oh HJ, Na HY, Lee HS, Shin CM, Park YS, Kim N, Lee DH. Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse. Inflamm Bowel Dis 2022:izab340. [PMID: 35016209 DOI: 10.1093/ibd/izab340] [Reference Citation Analysis]
223 Wu X, Pan S, Luo W, Shen Z, Meng X, Xiao M, Tan B, Nie K, Tong T, Wang X. Roseburia intestinalis‑derived flagellin ameliorates colitis by targeting miR‑223‑3p‑mediated activation of NLRP3 inflammasome and pyroptosis. Mol Med Rep 2020;22:2695-704. [PMID: 32700754 DOI: 10.3892/mmr.2020.11351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
224 Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2019;68:977-984. [PMID: 30420398 DOI: 10.1136/gutjnl-2018-317021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
225 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
226 Lv Q, Xing Y, Liu J, Dong D, Liu Y, Qiao H, Zhang Y, Hu L. Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation. Acta Pharm Sin B 2021;11:2880-99. [PMID: 34589402 DOI: 10.1016/j.apsb.2021.03.011] [Reference Citation Analysis]
227 Jin X, Bai X, Zhao Y, Dong Z, Pang J, Liu M, Liu X. Nrf2 Participates in M2 Polarization by Trichinella spiralis to Alleviate TNBS-Induced Colitis in Mice. Front Immunol 2021;12:698494. [PMID: 34249002 DOI: 10.3389/fimmu.2021.698494] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
228 Xing C, Zhang T, Liu X, Li C, Yang G, Zhang H, Wang R, Wang K, Miao Y, Lan D. Guanylin ligand protects the intestinal immune barrier by activating the guanylate cyclase-C signaling pathway. Acta Histochem 2021;124:151811. [PMID: 34920371 DOI: 10.1016/j.acthis.2021.151811] [Reference Citation Analysis]
229 Zhou T, Sheng Y, Guan H, Meng R, Wang Z. Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China. Front Public Health 2021;9:704889. [PMID: 34490187 DOI: 10.3389/fpubh.2021.704889] [Reference Citation Analysis]
230 Yao D, Dai W, Dong M, Dai C, Wu S. MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis. EBioMedicine 2021;74:103751. [PMID: 34902790 DOI: 10.1016/j.ebiom.2021.103751] [Reference Citation Analysis]
231 Kyodo R, Takeuchi I, Narumi S, Shimizu H, Hata K, Yoshioka T, Tanase-nakao K, Shimizu T, Arai K. Novel biallelic mutations in the DUOX2 gene underlying very early-onset inflammatory bowel disease: A case report. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.109015] [Reference Citation Analysis]
232 Liu XH, Wu XR, Lan N, Zheng XB, Zhou C, Hu T, Chen YF, Cai ZR, Chen ZX, Lan P, Wu XJ. CD73 promotes colitis-associated tumorigenesis in mice. Oncol Lett 2020;20:1221-30. [PMID: 32724362 DOI: 10.3892/ol.2020.11670] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
233 Magalhães HIR, Castelucci P. Enteric nervous system and inflammatory bowel diseases: Correlated impacts and therapeutic approaches through the P2X7 receptor. World J Gastroenterol 2021; 27(46): 7909-7924 [DOI: 10.3748/wjg.v27.i46.7909] [Reference Citation Analysis]
234 Le Cosquer G, Buscail E, Gilletta C, Deraison C, Duffas J, Bournet B, Tuyeras G, Vergnolle N, Buscail L. Incidence and Risk Factors of Cancer in the Anal Transitional Zone and Ileal Pouch following Surgery for Ulcerative Colitis and Familial Adenomatous Polyposis. Cancers 2022;14:530. [DOI: 10.3390/cancers14030530] [Reference Citation Analysis]
235 D'Amico F, Netter P, Baumann C, Veltin M, Zallot C, Aimone-Gastin I, Danese S, Peyrin-Biroulet L. Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. J Clin Med 2020;9:E2697. [PMID: 32825383 DOI: 10.3390/jcm9092697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
236 Furuse M, Hosomi S, Nishida Y, Itani S, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Nagami Y, Taira K, Kamata N, Watanabe T, Watanabe K, Fujiwara Y. The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients. PLoS One 2021;16:e0250597. [PMID: 33886687 DOI: 10.1371/journal.pone.0250597] [Reference Citation Analysis]
237 Albayrak NE, Polydorides AD. Characteristics and Outcomes of Left-sided Ulcerative Colitis With a Cecal/Periappendiceal Patch of Inflammation. Am J Surg Pathol 2022. [PMID: 35354161 DOI: 10.1097/PAS.0000000000001883] [Reference Citation Analysis]
238 Erculiani M, Zanatta C, Vidal E, Martelossi S, Midrio P. Ulcerative Colitis of the Neovagina in a Toddler with Cloaca and Chronic Kidney Disease. European J Pediatr Surg Rep 2021;9:e33-6. [PMID: 34026418 DOI: 10.1055/s-0041-1726868] [Reference Citation Analysis]
239 Roberts B. New-Onset Ulcerative Colitis in a Young Caucasian Woman with Unclassified Arteritis. Case Rep Vasc Med 2022;2022:7773222. [PMID: 35036022 DOI: 10.1155/2022/7773222] [Reference Citation Analysis]
240 Krzystek-Korpacka M, Fleszar MG, Bednarz-Misa I, Lewandowski Ł, Szczuka I, Kempiński R, Neubauer K. Transcriptional and Metabolomic Analysis of L-Arginine/Nitric Oxide Pathway in Inflammatory Bowel Disease and Its Association with Local Inflammatory and Angiogenic Response: Preliminary Findings. Int J Mol Sci 2020;21:E1641. [PMID: 32121248 DOI: 10.3390/ijms21051641] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
241 Lamb CA, Kirby JA, Keir ME, Mansfield JC. T Lymphocytes Expressing AlphaE Beta7 Integrin in Ulcerative Colitis: Associations With Cellular Lineage and Phenotype. J Crohns Colitis 2017;11:1504-5. [PMID: 28981704 DOI: 10.1093/ecco-jcc/jjx097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
242 Keshteli AH, Madsen KL, Dieleman LA. Diet in the Pathogenesis and Management of Ulcerative Colitis; A Review of Randomized Controlled Dietary Interventions. Nutrients 2019;11:E1498. [PMID: 31262022 DOI: 10.3390/nu11071498] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
243 Sun J, Xue P, Liu J, Huang L, Lin G, Ran K, Yang J, Lu C, Zhao YZ, Xu HL. Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomater Sci Eng 2021;7:4859-69. [PMID: 34547895 DOI: 10.1021/acsbiomaterials.1c00792] [Reference Citation Analysis]
244 Gao H, Li Y, Sun J, Xu H, Wang M, Zuo X, Fu Q, Guo Y, Chen Z, Zhang P, Li X, Wang N, Ye T, Yao Y. Saccharomyces boulardii Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Regulating NF-κB and Nrf2 Signaling Pathways. Oxid Med Cell Longev 2021;2021:1622375. [PMID: 34367460 DOI: 10.1155/2021/1622375] [Reference Citation Analysis]
245 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
246 Sun Y, Zhang Z, Zheng CQ, Sang LX. Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review. World J Gastroenterol 2021; 27(22): 2963-2978 [PMID: 34168401 DOI: 10.3748/wjg.v27.i22.2963] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Lv Q, Wang K, Qiao S, Yang L, Xin Y, Dai Y, Wei Z. Norisoboldine, a natural AhR agonist, promotes Treg differentiation and attenuates colitis via targeting glycolysis and subsequent NAD+/SIRT1/SUV39H1/H3K9me3 signaling pathway. Cell Death Dis 2018;9:258. [PMID: 29449535 DOI: 10.1038/s41419-018-0297-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
248 Zou J, Shen Y, Chen M, Zhang Z, Xiao S, Liu C, Wan Y, Yang L, Jiang S, Shang E, Qian D, Duan J. Lizhong decoction ameliorates ulcerative colitis in mice via modulating gut microbiota and its metabolites. Appl Microbiol Biotechnol. 2020;104:5999-6012. [PMID: 32418127 DOI: 10.1007/s00253-020-10665-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
249 Wang H, Zhang M, Zhang M, Wang F, Liu J, Zhao Q. Carboxypeptidase A6 was identified and validated as a novel potential biomarker for predicting the occurrence of active ulcerative colitis. J Cell Mol Med 2020;24:8803-13. [PMID: 32570281 DOI: 10.1111/jcmm.15517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
250 Chen G, Lissoos T, Dieyi C, Null KD. Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study. Inflamm Bowel Dis 2021;27:1177-83. [PMID: 33043982 DOI: 10.1093/ibd/izaa263] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
251 Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res 2019;17:36-44. [PMID: 30678445 DOI: 10.5217/ir.2018.00126] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
252 Römkens TEH, Te Morsche R, Peters W, Burger DM, Hoentjen F, Drenth JPH. Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice. Br J Clin Pharmacol 2018;84:477-81. [PMID: 29073323 DOI: 10.1111/bcp.13462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
253 Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Inflamm Bowel Dis 2019;25:803-10. [PMID: 30295811 DOI: 10.1093/ibd/izy304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
254 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 33.5] [Reference Citation Analysis]
255 Mishra A, Chung J, Mani H, Serrano M. Response to Mesalamine Therapy in Pediatric Collagenous Gastritis and Colitis: A Case Report and Review. Glob Pediatr Health 2022;9:2333794X221094262. [PMID: 35465197 DOI: 10.1177/2333794X221094262] [Reference Citation Analysis]
256 Ren J, Yue B, Wang H, Zhang B, Luo X, Yu Z, Zhang J, Ren Y, Mani S, Wang Z, Dou W. Acacetin Ameliorates Experimental Colitis in Mice via Inhibiting Macrophage Inflammatory Response and Regulating the Composition of Gut Microbiota. Front Physiol 2020;11:577237. [PMID: 33536931 DOI: 10.3389/fphys.2020.577237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
257 Ou AT, Zhang JX, Fang YF, Wang R, Tang XP, Zhao PF, Zhao YG, Zhang M, Huang YZ. Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases. Acta Pharmacol Sin 2020;42:1913-20. [PMID: 34561552 DOI: 10.1038/s41401-021-00770-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, daCosta DiBonaventura M. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol 2020;20:18. [PMID: 31964359 DOI: 10.1186/s12876-020-1164-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
259 Tepasse PR, Vollenberg R, Nowacki TM. Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand? Life (Basel) 2021;11:1220. [PMID: 34833096 DOI: 10.3390/life11111220] [Reference Citation Analysis]
260 Soontararak S, Chow L, Johnson V, Coy J, Wheat W, Regan D, Dow S. Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model. Stem Cells Transl Med 2018;7:456-67. [PMID: 29635868 DOI: 10.1002/sctm.17-0305] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 11.3] [Reference Citation Analysis]
261 Gareb B, Posthumus S, Beugeling M, Koopmans P, Touw DJ, Dijkstra G, Kosterink JGW, Frijlink HW. Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics 2019;11:E428. [PMID: 31450748 DOI: 10.3390/pharmaceutics11090428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
262 Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, Clare S, Harcourt K, MacDonald TT, Ray KP, Vossenkämper A, West MR, Crowe JS. Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep 2021;11:19422. [PMID: 34593832 DOI: 10.1038/s41598-021-97236-0] [Reference Citation Analysis]
263 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
264 Ren K, Yong C, Yuan H, Cao B, Zhao K, Wang J. TNF-α inhibits SCF, ghrelin, and substance P expressions through the NF-κB pathway activation in interstitial cells of Cajal. Braz J Med Biol Res 2018;51:e7065. [PMID: 29694505 DOI: 10.1590/1414-431x20187065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
265 Zheng XB, He XW, Zhang LJ, Qin HB, Lin XT, Liu XH, Zhou C, Liu HS, Hu T, Cheng HC, He XS, Wu XR, Chen YF, Ke J, Wu XJ, Lan P. Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice. Gastroenterol Rep (Oxf) 2019;7:127-38. [PMID: 30976426 DOI: 10.1093/gastro/goy017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
266 Matsunaga Y, Hasei S, Yamamotoya T, Honda H, Kushiyama A, Sakoda H, Fujishiro M, Ono H, Ito H, Okabe T, Asano T, Nakatsu Y. Pathological Role of Pin1 in the Development of DSS-Induced Colitis. Cells 2021;10:1230. [PMID: 34067858 DOI: 10.3390/cells10051230] [Reference Citation Analysis]
267 Zhou XL, Yang J, Qu XJ, Meng J, Miao RR, Cui SX. M10, a Myricetin-3-O-b-D-Lactose Sodium Salt, Prevents Ulcerative Colitis Through Inhibiting Necroptosis in Mice. Front Pharmacol 2020;11:557312. [PMID: 33041798 DOI: 10.3389/fphar.2020.557312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
268 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Kotze PG, Steinwurz F, Francisconi C, Zaltman C, Pinheiro M, Salese L, Ponce de Leon D. Review of the epidemiology and burden of ulcerative colitis in Latin America. Therap Adv Gastroenterol 2020;13:1756284820931739. [PMID: 32695230 DOI: 10.1177/1756284820931739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
270 Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500. [PMID: 28973005 DOI: 10.1371/journal.pone.0185500] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 11.2] [Reference Citation Analysis]
271 Vavricka SR, Greuter T, Cohen BL, Reinisch W, Steinwurz F, Fellmann M, Guo X, Lawendy N, Paulissen J, Peyrin-biroulet L. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. Therap Adv Gastroenterol 2022;15:175628482210908. [DOI: 10.1177/17562848221090834] [Reference Citation Analysis]
272 Kanazawa M, Tominaga K, Yamamiya A, Tanaka T, Watanabe S, Sugaya T, Abe K, Kanamori A, Arisaka T, Hoshi K, Iijima M, Goda K, Haruyama Y, Irisawa A. Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission. Healthcare (Basel) 2021;9:1405. [PMID: 34828451 DOI: 10.3390/healthcare9111405] [Reference Citation Analysis]
273 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
274 Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00222-6. [PMID: 33684552 DOI: 10.1016/j.cgh.2021.02.043] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
275 Ma Y, Hu C, Yan W, Jiang H, Liu G. Lactobacillus pentosus Increases the Abundance of Akkermansia and Affects the Serum Metabolome to Alleviate DSS-Induced Colitis in a Murine Model. Front Cell Dev Biol 2020;8:591408. [PMID: 33195257 DOI: 10.3389/fcell.2020.591408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
276 Cao L, Huang F, Massey IY, Wen C, Zheng S, Xu S, Yang F. Effects of Microcystin-LR on the Microstructure and Inflammation-Related Factors of Jejunum in Mice. Toxins (Basel) 2019;11:E482. [PMID: 31438657 DOI: 10.3390/toxins11090482] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
277 Lin L, Wang T, Lu Y, Chen P, Zhang Y, Zu X, Chen B, Mao R, Feng R, Cui Y, Zhang S, He Y. Mucosal healing and quality of life in therapeutic goals of ulcerative colitis: occurrence and related factors of functional bowel disorder-like symptoms. Therap Adv Gastroenterol 2022;15:175628482210925. [DOI: 10.1177/17562848221092597] [Reference Citation Analysis]
278 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
279 Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O'morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-biroulet L. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00297-1] [Reference Citation Analysis]
280 Chen G, Ran X, Li B, Li Y, He D, Huang B, Fu S, Liu J, Wang W. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. EBioMedicine. 2018;30:317-325. [PMID: 29627390 DOI: 10.1016/j.ebiom.2018.03.030] [Cited by in Crossref: 98] [Cited by in F6Publishing: 96] [Article Influence: 24.5] [Reference Citation Analysis]
281 Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
282 Andersen V, Pedersen AK, Möller S, Green A. Chronic Inflammatory Diseases - Diabetes Mellitus, Rheumatoid Arthritis, Coeliac Disease, Crohn's Disease, and Ulcerative Colitis Among the Offspring of Affected Parents: A Danish Population-Based Registry Study. Clin Epidemiol 2021;13:13-20. [PMID: 33442298 DOI: 10.2147/CLEP.S286623] [Reference Citation Analysis]
283 Shieh J, Chu TH, Liu Y, Kim J, Ruiz de Sabando A, Kobayashi S, Zee SY, Sheridan BS, Bialkowska AB, Yang VW. KLF5 protects the intestinal epithelium against Th17 immune response in a murine colitis model. JCI Insight 2022;7:e153488. [PMID: 35393949 DOI: 10.1172/jci.insight.153488] [Reference Citation Analysis]
284 Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02215-y] [Reference Citation Analysis]
285 Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel) 2021;11:2035. [PMID: 34443866 DOI: 10.3390/nano11082035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
286 Otten AT, Bourgonje AR, Peters V, Alizadeh BZ, Dijkstra G, Harmsen HJM. Vitamin C Supplementation in Healthy Individuals Leads to Shifts of Bacterial Populations in the Gut-A Pilot Study. Antioxidants (Basel) 2021;10:1278. [PMID: 34439526 DOI: 10.3390/antiox10081278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Wu N, Chen D, Sun H, Tan J, Zhang Y, Zhang T, Han Y, Liu H, Ouyang X, Yang XD, Niu X, Zhong J, Wang Z, Su B. MAP3K2 augments Th1 cell differentiation via IL-18 to promote T cell-mediated colitis. Sci China Life Sci 2021;64:389-403. [PMID: 32737854 DOI: 10.1007/s11427-020-1720-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
288 Wang K, Li YF, Lv Q, Li XM, Dai Y, Wei ZF. Bergenin, Acting as an Agonist of PPARγ, Ameliorates Experimental Colitis in Mice through Improving Expression of SIRT1, and Therefore Inhibiting NF-κB-Mediated Macrophage Activation. Front Pharmacol 2017;8:981. [PMID: 29375382 DOI: 10.3389/fphar.2017.00981] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
289 Zhang J, Wang X, Xu L, Zhang Z, Wang F, Tang X. Investigation of Potential Genetic Biomarkers and Molecular Mechanism of Ulcerative Colitis Utilizing Bioinformatics Analysis. Biomed Res Int 2020;2020:4921387. [PMID: 32190668 DOI: 10.1155/2020/4921387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
290 Gibiino G, Sartini A, Gitto S, Binda C, Sbrancia M, Coluccio C, Sambri V, Fabbri C. The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:2772. [PMID: 34444932 DOI: 10.3390/nu13082772] [Reference Citation Analysis]
291 Dubinsky MC, DiBonaventura M, Fan H, Bushmakin AG, Cappelleri JC, Maller E, Thorpe AJ, Salese L, Panés J. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies. Inflamm Bowel Dis 2021;27:983-93. [PMID: 32794567 DOI: 10.1093/ibd/izaa193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Wark G, Samocha-Bonet D, Ghaly S, Danta M. The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review. Nutrients 2020;13:E135. [PMID: 33396537 DOI: 10.3390/nu13010135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
293 Curciarello R, Sobande T, Jones S, Giuffrida P, Di Sabatino A, Docena GH, MacDonald TT, Kok K. Human Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. J Inflamm Res 2020;13:233-43. [PMID: 32547155 DOI: 10.2147/JIR.S234710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
294 Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis 2021;15:1130-41. [PMID: 33290538 DOI: 10.1093/ecco-jcc/jjaa249] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
295 Nachury M, Bouhnik Y, Serrero M, Filippi J, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Tadbiri S, Allez M, Viennot S, Bourreille A, Laharie D, Amiot A; GETAID-patient experience study group. Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. Dig Liver Dis 2021;53:434-41. [PMID: 33187920 DOI: 10.1016/j.dld.2020.10.020] [Reference Citation Analysis]
296 Zhang J, Xu M, Zhou W, Li D, Zhang H, Chen Y, Ning L, Zhang Y, Li S, Yu M, Chen Y, Zeng H, Cen L, Zhou T, Zhou X, Lu C, Yu C, Li Y, Sun J, Kong X, Shen Z. Deficiency in the anti-apoptotic protein DJ-1 promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease via p53. J Biol Chem 2020;295:4237-51. [PMID: 32075910 DOI: 10.1074/jbc.RA119.010143] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
297 Yan X, Yang C, Yang M, Ma Y, Zhang Y, Zhang Y, Liu C, Xu Q, Tu K, Zhang M. All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis. J Nanobiotechnology 2022;20:99. [PMID: 35236359 DOI: 10.1186/s12951-022-01299-8] [Reference Citation Analysis]
298 Han Z, Wang H, Guo D, Zhang J. Integrative transcriptomic and metabonomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis. Aging (Albany NY) 2021;13:5087-103. [PMID: 33535180 DOI: 10.18632/aging.202427] [Reference Citation Analysis]
299 Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panés J. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis 2021;27:816-25. [PMID: 32766762 DOI: 10.1093/ibd/izaa199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
300 Li Y, Soendergaard C, Bergenheim FH, Aronoff DM, Milne G, Riis LB, Seidelin JB, Jensen KB, Nielsen OH. COX-2-PGE2 Signaling Impairs Intestinal Epithelial Regeneration and Associates with TNF Inhibitor Responsiveness in Ulcerative Colitis. EBioMedicine 2018;36:497-507. [PMID: 30190207 DOI: 10.1016/j.ebiom.2018.08.040] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
301 Weisel K, Scott N, Berger S, Wang S, Brown K, Powell M, Broer M, Watts C, Tompson DJ, Burriss SW, Hawkins S, Abbott-Banner K, Tak PP. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol 2021;8:e000680. [PMID: 34389633 DOI: 10.1136/bmjgast-2021-000680] [Reference Citation Analysis]
302 Li H, Ye XF, Su YS, He W, Zhang JB, Zhang Q, Zhan LB, Jing XH. Mechanism of Acupuncture and Moxibustion on Promoting Mucosal Healing in Ulcerative Colitis. Chin J Integr Med 2022. [PMID: 35412218 DOI: 10.1007/s11655-022-3531-x] [Reference Citation Analysis]
303 Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J 2020;8:91-8. [PMID: 32213052 DOI: 10.1177/2050640619895361] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
304 Luo W, Shen Z, Deng M, Li X, Tan B, Xiao M, Wu S, Yang Z, Zhu C, Tian L, Wu X, Meng X, Quan Y, Wang X. Roseburia intestinalis supernatant ameliorates colitis induced in mice by regulating the immune response. Mol Med Rep 2019;20:1007-16. [PMID: 31173202 DOI: 10.3892/mmr.2019.10327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
305 Shimodaira Y, Onochi K, Watanabe K, Takahashi S, Fukuda S, Watanabe N, Koizumi S, Matsuhashi T, Iijima K. Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan. Intest Res 2021;19:225-31. [PMID: 32806877 DOI: 10.5217/ir.2020.00023] [Reference Citation Analysis]
306 Liu F, Wang X, Li D, Cui Y, Li X. Apple polyphenols extract alleviated dextran sulfate sodium-induced ulcerative colitis in C57BL/6 male mice by restoring bile acid metabolism disorder and gut microbiota dysbiosis. Phytother Res 2021;35:1468-85. [PMID: 33215776 DOI: 10.1002/ptr.6910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
307 Cao Z, Wang X, Pang Y, Cheng S, Liu J. Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment. Nat Commun 2019;10:5783. [PMID: 31857577 DOI: 10.1038/s41467-019-13727-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
308 Wang X, Xie L, Long J, Liu K, Lu J, Liang Y, Cao Y, Dai X, Li X. Therapeutic effect of baicalin on inflammatory bowel disease: A review. J Ethnopharmacol 2022;283:114749. [PMID: 34666140 DOI: 10.1016/j.jep.2021.114749] [Reference Citation Analysis]
309 Long Y, Zhao X, Liu C, Xia C, Liu C. Activated inducible co-stimulator-positive programmed cell death 1-positive follicular helper T cells indicate disease activity and severity in ulcerative colitis patients. Clin Exp Immunol 2020;202:106-18. [PMID: 32621310 DOI: 10.1111/cei.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
310 Georgila K, Vyrla D, Drakos E. Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer. Cancers (Basel). 2019;11:1097. [PMID: 31374929 DOI: 10.3390/cancers11081097] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
311 Frias Gomes C, Colombel JF, Torres J. De-escalation of Therapy in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20:35. [PMID: 29961926 DOI: 10.1007/s11894-018-0643-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
312 Al Khoury A, Xiao Y, Golovics PA, Kohen R, Afif W, Wild G, Friedman G, Galiatsatos P, Hilzenrat N, Szilagyi A, Wyse J, Cohen A, Bitton A, Bessissow T, Lakatos PL. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Dig Liver Dis 2021;53:980-6. [PMID: 33640302 DOI: 10.1016/j.dld.2021.02.006] [Reference Citation Analysis]
313 Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol 2022. [PMID: 35477319 DOI: 10.1080/1744666X.2022.2069562] [Reference Citation Analysis]
314 Long Y, Xia C, Xu L, Liu C, Fan C, Bao H, Zhao X, Liu C. The Imbalance of Circulating Follicular Helper T Cells and Follicular Regulatory T Cells Is Associated With Disease Activity in Patients With Ulcerative Colitis. Front Immunol 2020;11:104. [PMID: 32117258 DOI: 10.3389/fimmu.2020.00104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
315 Benmoussa A, Diallo I, Salem M, Michel S, Gilbert C, Sévigny J, Provost P. Concentrates of two subsets of extracellular vesicles from cow's milk modulate symptoms and inflammation in experimental colitis. Sci Rep 2019;9:14661. [PMID: 31601878 DOI: 10.1038/s41598-019-51092-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
316 Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 2021;:103017. [PMID: 34902606 DOI: 10.1016/j.autrev.2021.103017] [Reference Citation Analysis]
317 Wynne J, Kozuch P. Medical marijuana for inflammatory bowel disease: the highs and lows. Scand J Gastroenterol 2021;:1-9. [PMID: 34919496 DOI: 10.1080/00365521.2021.1998604] [Reference Citation Analysis]
318 Schineis C, Lehmann KS, Lauscher JC, Beyer K, Hartmann L, Margonis GA, Michel J, Degro CE, Loch FN, Speichinger F, Kreis ME, Kamphues C. Colectomy with ileostomy for severe ulcerative colitis-postoperative complications and risk factors.Int J Colorectal Dis. 2020;35:387-394. [PMID: 31865435 DOI: 10.1007/s00384-019-03494-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
319 Guan Y, Hao Y, Guan Y, Bu H, Wang H. Effects of vitamin D supplementation on blood markers in ulcerative colitis patients: a systematic review and meta-analysis. Eur J Nutr 2021. [PMID: 34075433 DOI: 10.1007/s00394-021-02603-2] [Reference Citation Analysis]
320 Vrdoljak J, Kumric M, Ticinovic Kurir T, Males I, Martinovic D, Vilovic M, Bozic J. Effects of Wine Components in Inflammatory Bowel Diseases. Molecules 2021;26:5891. [PMID: 34641434 DOI: 10.3390/molecules26195891] [Reference Citation Analysis]
321 Huang S, He J, Chen Y, Wang X, Li Y, Su Y, Wen R, Li X, Yang G, Luo S, Zhou L, Luo X. Effect of Huangqin decoction on regulating intestinal flora in colitis mice characterized as inhibition of the NOD2-dependent pathway. Pharm Biol 2022;60:108-18. [PMID: 34967696 DOI: 10.1080/13880209.2021.2017981] [Reference Citation Analysis]
322 Goodman WA, Basavarajappa SC, Liu AR, Rodriguez FDS, Mathes T, Ramakrishnan P. Sam68 contributes to intestinal inflammation in experimental and human colitis. Cell Mol Life Sci 2021. [PMID: 34693458 DOI: 10.1007/s00018-021-03976-7] [Reference Citation Analysis]
323 Chen Y, Li H, Lai L, Feng Q, Shen J. Identification of Common Differentially Expressed Genes and Potential Therapeutic Targets in Ulcerative Colitis and Rheumatoid Arthritis. Front Genet 2020;11:572194. [PMID: 33262784 DOI: 10.3389/fgene.2020.572194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
324 Mokros Ł, Domżał-Magrowska D, Pietras T, Sipowicz K, Talar-Wojnarowska R. The Association between Temperament, Chronotype, Depressive Symptoms, and Disease Activity among Patients with Inflammatory Bowel Disease-A Cross-Sectional Pilot Study. Life (Basel) 2021;11:1347. [PMID: 34947878 DOI: 10.3390/life11121347] [Reference Citation Analysis]
325 Jitsumura M, Cunningham AL, Hitchings MD, Islam S, Davies AP, Row PE, Riddell AD, Kinross J, Wilkinson TS, Jenkins GJ, Williams JG, Harris DA. Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study. BMJ Open 2018;8:e021987. [PMID: 30341117 DOI: 10.1136/bmjopen-2018-021987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
326 Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, Danese S, Peyrin-Biroulet L. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34453143 DOI: 10.1038/s41575-021-00492-8] [Reference Citation Analysis]
327 Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Chmielnicki J, Filip R, Pękala A, Janiak M, Skrobot K, Kasińska E, Krogulecki M, Królikowski P, Kłopocka M, Liebert A, Poniewierka E, Smoła I, Gąsiorowska A, Kaczka A, Wypych J, Wojciechowski K, Drygała S, Zagórowicz E. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol 2021;14:17562848211036456. [PMID: 34484422 DOI: 10.1177/17562848211036456] [Reference Citation Analysis]
328 Nishikawa H, Nakamura S, Miyazaki T, Kakimoto K, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance. J Clin Med 2021;10:4214. [PMID: 34575326 DOI: 10.3390/jcm10184214] [Reference Citation Analysis]
329 Pasvol TJ, Horsfall L, Bloom S, Segal AW, Sabin C, Field N, Rait G. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open 2020;10:e036584. [PMID: 32690524 DOI: 10.1136/bmjopen-2019-036584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
330 Li DF, Chang X, Zhao JL, Chen XM, Xu ZL, Zhang DG, Wu BH, Wang LS, Bai Y, Yao J. Colonic Epithelial PHLPP2 Deficiency Promotes Colonic Epithelial Pyroptosis by Activating the NF-κB Signaling Pathway. Oxid Med Cell Longev 2021;2021:5570731. [PMID: 34394827 DOI: 10.1155/2021/5570731] [Reference Citation Analysis]
331 Liu Y, Li BG, Su YH, Zhao RX, Song P, Li H, Cui XH, Gao HM, Zhai RX, Fu XJ, Ren X. Potential activity of Traditional Chinese Medicine against Ulcerative colitis: A review. J Ethnopharmacol 2022;:115084. [PMID: 35134488 DOI: 10.1016/j.jep.2022.115084] [Reference Citation Analysis]
332 Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis 2021;15:950-9. [PMID: 33475734 DOI: 10.1093/ecco-jcc/jjab016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C. Diagnostics (Basel). 2020;10. [PMID: 33276638 DOI: 10.3390/diagnostics10121037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
334 Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J Gastroenterol 2019; 25(31): 4414-4426 [PMID: 31496621 DOI: 10.3748/wjg.v25.i31.4414] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
335 Ye B, Lai L. Yu Shi An Chang Fang Ameliorates TNBS-Induced Colitis in Mice by Reducing Inflammatory Response and Protecting the Intestinal Mucosal Barrier. Evid Based Complement Alternat Med 2021;2021:8870901. [PMID: 34055024 DOI: 10.1155/2021/8870901] [Reference Citation Analysis]
336 Bjerrum JT, Steenholdt C, Ainsworth M, Nielsen OH, Reed MA, Atkins K, Günther UL, Hao F, Wang Y. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Med 2017;15:184. [PMID: 29032767 DOI: 10.1186/s12916-017-0949-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
337 Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
338 Sen A, Stark H. Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis. World J Gastroenterol 2019; 25(23): 2846-2862 [PMID: 31249444 DOI: 10.3748/wjg.v25.i23.2846] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
339 Agrawal M, Petralia F, Tepler A, Durbin L, Reinisch W, Colombel JF, Shah SC. Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. Inflamm Bowel Dis 2022:izac067. [PMID: 35366313 DOI: 10.1093/ibd/izac067] [Reference Citation Analysis]
340 Raj V, Venkataraman B, Almarzooqi S, Chandran S, Ojha SK, Attoub S, Adrian TE, Subramanya SB. Nerolidol Mitigates Colonic Inflammation: An Experimental Study Using both In Vivo and In Vitro Models. Nutrients 2020;12:E2032. [PMID: 32650602 DOI: 10.3390/nu12072032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
341 Lasa J, Correa G, Fuxman C, Garbi L, Linares ME, Lubrano P, Rausch A, Toro M, Yantorno M, Zubiaurre I, Peyrin-Biroulet L, Olivera P. Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study. Gastroenterol Res Pract 2020;2020:4060648. [PMID: 32411197 DOI: 10.1155/2020/4060648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
342 Friedrich M, Pohin M, Jackson MA, Korsunsky I, Bullers SJ, Rue-Albrecht K, Christoforidou Z, Sathananthan D, Thomas T, Ravindran R, Tandon R, Peres RS, Sharpe H, Wei K, Watts GFM, Mann EH, Geremia A, Attar M, McCuaig S, Thomas L, Collantes E, Uhlig HH, Sansom SN, Easton A, Raychaudhuri S, Travis SP, Powrie FM; Oxford IBD Cohort Investigators., Roche Fibroblast Network Consortium. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat Med 2021;27:1970-81. [PMID: 34675383 DOI: 10.1038/s41591-021-01520-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
343 Dhillon P, Singh K. Therapeutic applications of probiotics in ulcerative colitis: An updated review. PharmaNutrition 2020;13:100194. [DOI: 10.1016/j.phanu.2020.100194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
344 Franzin M, Stefančič K, Lucafò M, Decorti G, Stocco G. Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens 2021;10:211. [PMID: 33669168 DOI: 10.3390/pathogens10020211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
345 Zheng K, Jia J, Yan S, Shen H, Zhu P, Yu J. Paeoniflorin ameliorates ulcerative colitis by modulating the dendritic cell-mediated TH17/Treg balance. Inflammopharmacology 2020;28:1705-16. [PMID: 32472435 DOI: 10.1007/s10787-020-00722-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
346 Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol. 2018;31:14-23. [PMID: 29333063 DOI: 10.20524/aog.2017.0208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
347 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
348 Wang Y, Xie Q, Zhang Y, Ma W, Ning K, Xiang JY, Cui J, Xiang H. Combination of probiotics with different functions alleviate DSS-induced colitis by regulating intestinal microbiota, IL-10, and barrier function. Appl Microbiol Biotechnol 2020;104:335-49. [PMID: 31758237 DOI: 10.1007/s00253-019-10259-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
349 Gomes TNF, de Azevedo FS, Argollo M, Miszputen SJ, Ambrogini O Jr. Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil. Clin Exp Gastroenterol 2021;14:91-102. [PMID: 33762838 DOI: 10.2147/CEG.S288688] [Reference Citation Analysis]
350 Zhu M, Mu JX, Jiang MS, Mukherjee A, Zeng Z, Chen YD, Yang XL, Zhang H. Chinese research into ulcerative colitis from 1978 to 2017: A bibliometric analysis. World J Meta-Anal 2020; 8(2): 163-172 [DOI: 10.13105/wjma.v8.i2.163] [Reference Citation Analysis]
351 Okuno H, Ogino H, Ihara E, Nishioka K, Tanaka Y, Chinen T, Kohjima M, Oono T, Tanaka M, Goya T, Fujimori N, Iboshi Y, Gotoda T, Ogawa Y. Discriminant equation using mucosally expressed cytokines and transcription factor for making definite diagnosis of inflammatory bowel disease unclassified. BMC Gastroenterol 2021;21:73. [PMID: 33593285 DOI: 10.1186/s12876-021-01656-1] [Reference Citation Analysis]
352 Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H. Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. Intest Res 2021;19:53-61. [PMID: 32312035 DOI: 10.5217/ir.2019.09146] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
353 Dai L, Zhang D, Qian Y, Wan Y, Chang S, Qian H. STAT6 rs324015 Gene Polymorphism Increases Ulcerative Colitis Risk: A Case-Control Study. Pharmgenomics Pers Med 2021;14:101-7. [PMID: 33500651 DOI: 10.2147/PGPM.S271327] [Reference Citation Analysis]
354 Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J; HIBISCUS Study Group. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol 2022;7:17-27. [PMID: 34798036 DOI: 10.1016/S2468-1253(21)00338-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Shinohara R, Sasaki K, Inoue J, Hoshi N, Fukuda I, Sasaki D, Kondo A, Osawa R. Butyryl-CoA:acetate CoA-transferase gene associated with the genus Roseburia is decreased in the gut microbiota of Japanese patients with ulcerative colitis. Biosci Microbiota Food Health 2019;38:159-63. [PMID: 31763119 DOI: 10.12938/bmfh.18-029] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
356 Zhu MY, Sun LQ. Ulcerative colitis complicated with colonic necrosis, septic shock and venous thromboembolism: A case report. World J Clin Cases 2019; 7(16): 2360-2366 [PMID: 31531332 DOI: 10.12998/wjcc.v7.i16.2360] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
357 Zhang H, Lang W, Liu X, Bai J, Jia Q, Shi Q. Procyanidin A1 alleviates DSS-induced ulcerative colitis via regulating AMPK/mTOR/p70S6K-mediated autophagy. J Physiol Biochem 2022. [PMID: 35001346 DOI: 10.1007/s13105-021-00854-5] [Reference Citation Analysis]
358 Han H, Sun W, Feng L, Wen Z, Yang M, Ma Y, Fu J, Ma X, Xu X, Wang Z, Yin T, Wang XM, Lu GH, Qi JL, Lin H, Yang Y. Differential relieving effects of shikonin and its derivatives on inflammation and mucosal barrier damage caused by ulcerative colitis. PeerJ 2021;9:e10675. [PMID: 33505807 DOI: 10.7717/peerj.10675] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
359 Palazzo L, Mikolčević P, Mikoč A, Ahel I. ADP-ribosylation signalling and human disease. Open Biol 2019;9:190041. [PMID: 30991935 DOI: 10.1098/rsob.190041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
360 Castro-Dopico T, Colombel JF, Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Curr Opin Pharmacol 2020;55:90-8. [PMID: 33166872 DOI: 10.1016/j.coph.2020.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
361 Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, Mary C, Kerdreux E, Gauttier V, Kucik A, Thepenier V, Martin JC, Chang C, Rahman A, Guen NS, Braudeau C, Abidi A, David G, Malard F, Takoudju C, Martinet B, Gérard N, Neveu I, Neunlist M, Coron E, MacDonald TT, Desreumaux P, Mai HL, Le Bas-Bernardet S, Mosnier JF, Merad M, Josien R, Brouard S, Soulillou JP, Blancho G, Bourreille A, Naveilhan P, Vanhove B, Poirier N. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 2019;129:1910-25. [PMID: 30939120 DOI: 10.1172/JCI121668] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
362 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
363 Freeman K, Willis BH, Fraser H, Taylor-Phillips S, Clarke A. Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. BMJ Open. 2019;9:e027428. [PMID: 30852550 DOI: 10.1136/bmjopen-2018-027428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
364 Zhu F, Ke Y, Luo Y, Wu J, Wu P, Ma F, Liu Y. Effects of Different Treatment of Fecal Microbiota Transplantation Techniques on Treatment of Ulcerative Colitis in Rats. Front Microbiol 2021;12:683234. [PMID: 34335508 DOI: 10.3389/fmicb.2021.683234] [Reference Citation Analysis]
365 Yue X, Wen S, Long-Kun D, Man Y, Chang S, Min Z, Shuang-Yu L, Xin Q, Jie M, Liang W. Three important short-chain fatty acids (SCFAs) attenuate the inflammatory response induced by 5-FU and maintain the integrity of intestinal mucosal tight junction. BMC Immunol 2022;23:19. [PMID: 35448938 DOI: 10.1186/s12865-022-00495-3] [Reference Citation Analysis]
366 Miyazaki C, Sakashita T, Jung W, Kato S. Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis. Adv Ther 2021;38:2229-47. [PMID: 33515423 DOI: 10.1007/s12325-020-01615-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Wu B, Zhou Q, He Z, Wang X, Sun X, Chen Y. Protective Effect of the Abelmoschus manihot Flower Extract on DSS-Induced Ulcerative Colitis in Mice. Evid Based Complement Alternat Med 2021;2021:7422792. [PMID: 34408782 DOI: 10.1155/2021/7422792] [Reference Citation Analysis]
368 Di Ruscio M, Variola A, Angheben A, Resimini S, Geccherle A, Ruffo G, Barugola G. A Challenging Colectomy for Acute Severe Ulcerative Colitis Complicated by COVID-19. Inflamm Bowel Dis 2020;26:e120-2. [PMID: 32626898 DOI: 10.1093/ibd/izaa186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
369 Snell A, Segal J, Limdi J, Banerjee R. Inflammatory bowel disease in India: challenges and opportunities. Frontline Gastroenterol 2021;12:390-6. [DOI: 10.1136/flgastro-2020-101500] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
370 Hennessy O, Egan L, Joyce M. Subtotal colectomy in ulcerative colitis—long term considerations for the rectal stump. World J Gastrointest Surg 2021; 13(2): 198-209 [PMID: 33643539 DOI: 10.4240/wjgs.v13.i2.198] [Reference Citation Analysis]
371 Davis W, Vavilin I, Malhotra N. Biologic Therapy in HIV: To Screen or Not to Screen. Cureus 2021;13:e15941. [PMID: 34336440 DOI: 10.7759/cureus.15941] [Reference Citation Analysis]
372 Kaur L, Gordon M, Baines PA, Iheozor-Ejiofor Z, Sinopoulou V, Akobeng AK. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;3:CD005573. [PMID: 32128795 DOI: 10.1002/14651858.CD005573.pub3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
373 Huang R, Wang K, Gao L, Gao W. TIMP1 Is A Potential Key Gene Associated With The Pathogenesis And Prognosis Of Ulcerative Colitis-Associated Colorectal Cancer. Onco Targets Ther 2019;12:8895-904. [PMID: 31802901 DOI: 10.2147/OTT.S222608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
374 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
375 Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. Dig Dis Sci 2019;64:2478-88. [PMID: 30923985 DOI: 10.1007/s10620-019-05594-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
376 Suárez-Fariñas M, Tokuyama M, Wei G, Huang R, Livanos A, Jha D, Levescot A, Irizar H, Kosoy R, Cording S, Wang W, Losic B, Ungaro RC, Di'Narzo A, Martinez-Delgado G, Suprun M, Corley MJ, Stojmirovic A, Houten SM, Peters L, Curran M, Brodmerkel C, Perrigoue J, Friedman JR, Hao K, Schadt EE, Zhu J, Ko HM, Cho J, Dubinsky MC, Sands BE, Ndhlovu L, Cerf-Bensusan N, Kasarskis A, Colombel JF, Harpaz N, Argmann C, Mehandru S. Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease. Gastroenterology 2021;160:287-301.e20. [PMID: 32980345 DOI: 10.1053/j.gastro.2020.09.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
377 Ke H, Li F, Deng W, Li Z, Wang S, Lv P, Chen Y. Metformin Exerts Anti-inflammatory and Mucus Barrier Protective Effects by Enriching Akkermansia muciniphila in Mice With Ulcerative Colitis. Front Pharmacol 2021;12:726707. [PMID: 34658866 DOI: 10.3389/fphar.2021.726707] [Reference Citation Analysis]
378 Uzzan M, Tokuyama M, Rosenstein AK, Tomescu C, SahBandar IN, Ko HM, Leyre L, Chokola A, Kaplan-Lewis E, Rodriguez G, Seki A, Corley MJ, Aberg J, La Porte A, Park EY, Ueno H, Oikonomou I, Doron I, Iliev ID, Chen BK, Lui J, Schacker TW, Furtado GC, Lira SA, Colombel JF, Horowitz A, Lim JK, Chomont N, Rahman AH, Montaner LJ, Ndhlovu LC, Mehandru S. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. Sci Transl Med 2018;10:eaau4711. [PMID: 30282696 DOI: 10.1126/scitranslmed.aau4711] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
379 Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflamm Intest Dis 2021;6:186-98. [PMID: 35083284 DOI: 10.1159/000519123] [Reference Citation Analysis]
380 Paulides E, Pasma A, Erler NS, van Eijk RLA, de Vries AC, van der Woude CJ. Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34181168 DOI: 10.1007/s10620-021-07118-8] [Reference Citation Analysis]
381 Xue X, Bredell BX, Anderson ER, Martin A, Mays C, Nagao-Kitamoto H, Huang S, Győrffy B, Greenson JK, Hardiman K, Spence JR, Kamada N, Shah YM. Quantitative proteomics identifies STEAP4 as a critical regulator of mitochondrial dysfunction linking inflammation and colon cancer. Proc Natl Acad Sci U S A 2017;114:E9608-17. [PMID: 29078383 DOI: 10.1073/pnas.1712946114] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
382 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
383 Chimenti MS, Conigliaro P, Biancone L, Perricone R. Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. Ther Adv Musculoskelet Dis 2021;13:1759720X20977777. [PMID: 33680096 DOI: 10.1177/1759720X20977777] [Reference Citation Analysis]
384 Cluny NL, Nyuyki KD, Almishri W, Griffin L, Lee BH, Hirota SA, Pittman QJ, Swain MG, Sharkey KA. Recruitment of α4β7 monocytes and neutrophils to the brain in experimental colitis is associated with elevated cytokines and anxiety-like behavior. J Neuroinflammation 2022;19:73. [PMID: 35379260 DOI: 10.1186/s12974-022-02431-z] [Reference Citation Analysis]
385 Nie K, Yi J, Yang Y, Deng M, Yang Y, Wang T, Chen X, Zhang Z, Wang X. A Broad m6A Modification Landscape in Inflammatory Bowel Disease. Front Cell Dev Biol 2022;9:782636. [DOI: 10.3389/fcell.2021.782636] [Reference Citation Analysis]
386 Brookes MJ, Waller J, Cappelleri JC, Modesto I, DiBonaventura MD, Bohm N, Mokgokong R, Massey O, Wood R, Bargo D. Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. BMJ Open Gastroenterol 2020;7:e000456. [PMID: 32938582 DOI: 10.1136/bmjgast-2020-000456] [Reference Citation Analysis]
387 Schreiber S, Irving PM, Sharara AI, Martín-Arranz MD, Hébuterne X, Penchev P, Danese S, Anthopoulos P, Akhundova-Unadkat G, Baert F. Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions. Aliment Pharmacol Ther 2022. [PMID: 35132657 DOI: 10.1111/apt.16781] [Reference Citation Analysis]
388 Bertani L, Barberio B, Tricò D, Zanzi F, Maniero D, Ceccarelli L, Marsilio I, Coppini F, Lorenzon G, Mumolo MG, Zingone F, Costa F, Savarino EV. Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. J Clin Med 2021;10:3270. [PMID: 34362053 DOI: 10.3390/jcm10153270] [Reference Citation Analysis]
389 Toyonaga T, Araba KC, Kennedy MM, Keith BP, Wolber EA, Beasley C, Steinbach EC, Schaner MR, Jain A, Long MD, Barnes EL, Herfarth HH, Isaacs KL, Hansen JJ, Kapadia MR, Guillem JG, Gulati AS, Sethupathy P, Furey TS, Ehre C, Sheikh SZ. Increased colonic expression of ACE2 associates with poor prognosis in Crohn's disease. Sci Rep 2021;11:13533. [PMID: 34188154 DOI: 10.1038/s41598-021-92979-2] [Reference Citation Analysis]
390 Luo W, Tian L, Tan B, Shen Z, Xiao M, Wu S, Meng X, Wu X, Wang X. Update: Innate Lymphoid Cells in Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 33609209 DOI: 10.1007/s10620-021-06831-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Novaković A. Modern therapy for inflammatory bowel disease. Arhiv za farmaciju 2017;67:112-23. [DOI: 10.5937/arhfarm1702112n] [Reference Citation Analysis]
392 Juliao-baños F, Puentes F, López R, Saffon M, Reyes G, Parra V, Galiano M, Barraza M, Molano J, Álvarez E, Corrales R, Vargas L, Gil F, Álvarez P, Limas L, Prieto R, Yance P, Díaz F, Bareño J, Juliao-baños F, Arrubla M, Camargo J, Puentes F, Arango L, López R, García R, Mendoza B, Saffon MA, Roldan LF, Zuleta J, Reyes G, Parra V, Flórez C, Nuñez E, Galiano MT, Barraza M, Sanchez IC, Molano JL, Lizarazo JI, Cuellar I, Álvarez E, Corrales R, Gil F, Vargas LE, Álvarez P, Limas LM, Prieto R, Ballén H, Delgado L, Yance P, Díaz F. Characterization of inflammatory bowel disease in Colombia: Results of a national register. Revista de Gastroenterología de México (English Edition) 2021;86:153-62. [DOI: 10.1016/j.rgmxen.2020.05.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Yang L, Luo H, Tan D, Zhang S, Zhong Z, Wang S, Vong CT, Wang Y. A recent update on the use of Chinese medicine in the treatment of inflammatory bowel disease. Phytomedicine 2021;92:153709. [PMID: 34560518 DOI: 10.1016/j.phymed.2021.153709] [Reference Citation Analysis]
394 Chen Y, Lei J, He S. m6A Modification Mediates Mucosal Immune Microenvironment and Therapeutic Response in Inflammatory Bowel Disease. Front Cell Dev Biol 2021;9:692160. [PMID: 34422815 DOI: 10.3389/fcell.2021.692160] [Reference Citation Analysis]
395 Hibi T, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T. Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. Inflamm Intest Dis 2020;5:27-35. [PMID: 32232052 DOI: 10.1159/000505092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
396 Kimura K, Yoshida A, Katagiri F, Takayanagi R, Yamada Y. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharm Drug Dispos 2019;40:250-61. [PMID: 31256430 DOI: 10.1002/bdd.2198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Lu A, Tao L, Li Q, Zhang J, Tang M, Yu W, Wang Y, Ai Z, Zhao Y, Liu H, Wu X. The rationale for using Periplaneta americana as a monarch drug of TCM in the treatment of damp-heat ulcerative colitis. Informatics in Medicine Unlocked 2021;26:100746. [DOI: 10.1016/j.imu.2021.100746] [Reference Citation Analysis]
398 Venkateswaran S, Prince J, Cutler DJ, Marigorta UM, Okou DT, Prahalad S, Mack D, Boyle B, Walters T, Griffiths A, Sauer CG, LeLeiko N, Keljo D, Markowitz J, Baker SS, Rosh J, Pfefferkorn M, Heyman MB, Patel A, Otley A, Baldassano R, Noe J, Rufo P, Oliva-Hemker M, Davis S, Zwick ME, Gibson G, Denson LA, Hyams J, Kugathasan S. Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis. Inflamm Bowel Dis 2018;24:829-38. [PMID: 29562276 DOI: 10.1093/ibd/izx084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
399 Godínez-Méndez LA, Gurrola-Díaz CM, Zepeda-Nuño JS, Vega-Magaña N, Lopez-Roa RI, Íñiguez-Gutiérrez L, García-López PM, Fafutis-Morris M, Delgado-Rizo V. In Vivo Healthy Benefits of Galacto-Oligosaccharides from Lupinus albus (LA-GOS) in Butyrate Production through Intestinal Microbiota. Biomolecules 2021;11:1658. [PMID: 34827656 DOI: 10.3390/biom11111658] [Reference Citation Analysis]
400 Oh CK, Lee HH, Kim JS, Lee B, Cho Y. Appendiceal Orifice Inflammation Is Associated with Lower Rate of Complete Endoscopic Remission in Patients with Ulcerative Colitis. JPM 2022;12:748. [DOI: 10.3390/jpm12050748] [Reference Citation Analysis]
401 Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol 2019;17:2497-2505.e1. [PMID: 30625408 DOI: 10.1016/j.cgh.2018.12.040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
402 Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
403 Zhang SL, Wang SN, Miao CY. Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention. Front Immunol 2017;8:1674. [PMID: 29234327 DOI: 10.3389/fimmu.2017.01674] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
404 Guillo L, D'Amico F, Serrero M, Angioi K, Loeuille D, Costanzo A, Danese S, Peyrin-Biroulet L. Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. United European Gastroenterol J 2020;8:1013-30. [PMID: 32778004 DOI: 10.1177/2050640620950093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
405 Huang J, Zhang J, Wang Y, Ma J, Yang X, Guo X, Lv M, Ma J, Zheng Y, Wang F, Tang X, Pandurangan A. Science Evidence of Chinese Herbal Medicine (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis. Gastroenterology Research and Practice 2022;2022:1-8. [DOI: 10.1155/2022/7942845] [Reference Citation Analysis]
406 Loktionov A. Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders. World J Gastroenterol 2019; 25(27): 3503-3526 [PMID: 31367153 DOI: 10.3748/wjg.v25.i27.3503] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
407 Mo Z, Tang J, Wu Z, Chen D, Xie D, Wang P. Ulcerative colitis triggered by pegylated interferon alpha-2b in a patient with chronic hepatitis B: A case report and literature review. Liver Research 2021;5:97-101. [DOI: 10.1016/j.livres.2021.04.001] [Reference Citation Analysis]
408 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
409 Wallden A, Graff P, Bryngelsson IL, Fornander L, Wiebert P, Vihlborg P. Risks of developing ulcerative colitis and Crohn's disease in relation to silica dust exposure in Sweden: a case-control study. BMJ Open 2020;10:e034752. [PMID: 32066610 DOI: 10.1136/bmjopen-2019-034752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
410 Iheozor-Ejiofor Z, Kaur L, Gordon M, Baines PA, Sinopoulou V, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;3:CD007443. [PMID: 32128794 DOI: 10.1002/14651858.CD007443.pub3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
411 Kameyama H, Nagahashi M, Shimada Y, Tajima Y, Ichikawa H, Nakano M, Sakata J, Kobayashi T, Narayanan S, Takabe K, Wakai T. Genomic characterization of colitis-associated colorectal cancer. World J Surg Oncol 2018;16:121. [PMID: 29966533 DOI: 10.1186/s12957-018-1428-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
412 Marafini I, Longo L, Lavasani DM, Rossi R, Salvatori S, Pianigiani F, Calabrese E, Siracusano A, Lorenzo GD, Monteleone G. High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1387. [PMID: 32397198 DOI: 10.3390/jcm9051387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
413 Bersuder E, Terciolo C, Lechevrel M, Martin E, Quesnelle C, Freund JN, Reimund JM, Gross I. Mesalazine initiates an anti-oncogenic β-catenin / MUCDHL negative feed-back loop in colon cancer cells by cell-specific mechanisms. Biomed Pharmacother 2021;146:112543. [PMID: 34929577 DOI: 10.1016/j.biopha.2021.112543] [Reference Citation Analysis]
414 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
415 Li H, Mo Y, Huang C, Ren Q, Xia X, Nan X, Shuai X, Meng X. An MSCT-based radiomics nomogram combined with clinical factors can identify Crohn's disease and ulcerative colitis. Ann Transl Med 2021;9:572. [PMID: 33987270 DOI: 10.21037/atm-21-1023] [Reference Citation Analysis]
416 Wang Y, Zhang H, He H, Ai K, Yu W, Xiao X, Qin Y, Zhang L, Xiong H, Zhou G. LRCH1 suppresses migration of CD4+ T cells and refers to disease activity in ulcerative colitis. Int J Med Sci 2020;17:599-608. [PMID: 32210709 DOI: 10.7150/ijms.39106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Voskuil MD, Spekhorst LM, van der Sloot KWJ, Jansen BH, Dijkstra G, van der Woude CJ, Hoentjen F, Pierik MJ, van der Meulen AE, de Boer NKH, Löwenberg M, Oldenburg B, Festen EAM, Weersma RK. Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes. J Crohns Colitis 2021;15:930-7. [PMID: 33152062 DOI: 10.1093/ecco-jcc/jjaa223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
418 Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther 2019;49:873-9. [PMID: 30773667 DOI: 10.1111/apt.15177] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
419 Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
420 AlRuthia Y, Alharbi O, Aljebreen AM, Azzam NA, Almadi MA, Bahari OH, Almalki KA, Atham AT, Alanazi AS, Saeed M, HajkhderMullaissa B, Alsenaidy M, Balkhi B. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Eff Resour Alloc 2019;17:25. [PMID: 31827409 DOI: 10.1186/s12962-019-0194-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
421 Ye X, Wang Y, Wang HHX, Feng R, Ye Z, Han J, Li L, Zeng Z, Chen M, Zhang S. Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. Therap Adv Gastroenterol 2021;14:1756284821994741. [PMID: 33717211 DOI: 10.1177/1756284821994741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Jentzer A, Veyrard P, Roblin X, Saint-Sardos P, Rochereau N, Paul S, Bourlet T, Pozzetto B, Pillet S. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms 2020;8:E1078. [PMID: 32698383 DOI: 10.3390/microorganisms8071078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
423 Curciarello R, Canziani KE, Salto I, Barbiera Romero E, Rocca A, Doldan I, Peton E, Brayer S, Sambuelli AM, Goncalves S, Tirado P, Correa GJ, Yantorno M, Garbi L, Docena GH, Serradell MLÁ, Muglia CI. Probiotic Lactobacilli Isolated from Kefir Promote Down-Regulation of Inflammatory Lamina Propria T Cells from Patients with Active IBD. Front Pharmacol 2021;12:658026. [PMID: 33935778 DOI: 10.3389/fphar.2021.658026] [Reference Citation Analysis]
424 Tavakoli A, Shirzad M, Taghavi A, Fattahi M, Ahmadian-Attari M, Mohammad Taghizadeh L, Rostami Chaijan M, Sedigh Rahimabadi M, Akrami R, Pasalar M. Efficacy of Rose Oil Soft Capsules on Clinical Outcomes in Ulcerative Colitis: A Pilot Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Galen Med J 2019;8:e1307. [PMID: 34466491 DOI: 10.31661/gmj.v8i0.1307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
425 Teich N, Grümmer H, Jörgensen E, Liceni T, Holtkamp-Endemann F, Fischer T, Hohenberger S. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months. BMC Gastroenterol 2021;21:161. [PMID: 33845784 DOI: 10.1186/s12876-021-01747-z] [Reference Citation Analysis]
426 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
427 Fleming A, Castro-Dopico T, Clatworthy MR. B cell class switching in intestinal immunity in health and disease. Scand J Immunol 2022;95:e13139. [PMID: 34978077 DOI: 10.1111/sji.13139] [Reference Citation Analysis]
428 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Yu T, Chu S, Liu X, Li J, Chen Q, Xu M, Wu H, Li M, Dong Y, Zhu F, Zhou H, Hu D, Fan H. Extracellular vesicles derived from EphB2-overexpressing bone marrow mesenchymal stem cells ameliorate DSS-induced colitis by modulating immune balance. Stem Cell Res Ther 2021;12:181. [PMID: 33722292 DOI: 10.1186/s13287-021-02232-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
430 Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther 2022. [PMID: 35014040 DOI: 10.1111/apt.16753] [Reference Citation Analysis]
431 Yue B, Ren J, Yu Z, Luo X, Ren Y, Zhang J, Mani S, Wang Z, Dou W. Pinocembrin alleviates ulcerative colitis in mice via regulating gut microbiota, suppressing TLR4/MD2/NF-κB pathway and promoting intestinal barrier. Biosci Rep 2020;40:BSR20200986. [PMID: 32687156 DOI: 10.1042/BSR20200986] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
432 Angelison L, Almer S, Davidsdottir L, Hammarlund P, Lindgren S, Hindorf U, Marsal J, Hertervig E. Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study. Scand J Gastroenterol 2020;55:154-62. [PMID: 31961234 DOI: 10.1080/00365521.2020.1713210] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
433 Antoniussen CS, Rasmussen HH, Holst M, Lauridsen C. Reducing Disease Activity of Inflammatory Bowel Disease by Consumption of Plant-Based Foods and Nutrients. Front Nutr 2021;8:733433. [PMID: 34957174 DOI: 10.3389/fnut.2021.733433] [Reference Citation Analysis]
434 Cui DJ, Yang XL, Okuda S, Ling YW, Zhang ZX, Liu Q, Yuan WQ, Yan F. Gallincin ameliorates colitis-associated inflammation and barrier function in mice based on network pharmacology prediction. J Int Med Res 2020;48:300060520951023. [PMID: 33322986 DOI: 10.1177/0300060520951023] [Reference Citation Analysis]
435 Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)., Working panel., Review panel. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00137-2. [PMID: 35184989 DOI: 10.1016/j.dld.2022.01.127] [Reference Citation Analysis]
436 Lai Y, Xue J, Liu CW, Gao B, Chi L, Tu P, Lu K, Ru H. Serum Metabolomics Identifies Altered Bioenergetics, Signaling Cascades in Parallel with Exposome Markers in Crohn's Disease. Molecules 2019;24:E449. [PMID: 30691236 DOI: 10.3390/molecules24030449] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
437 O'Connell L, Winter DC, Aherne CM. The Role of Organoids as a Novel Platform for Modeling of Inflammatory Bowel Disease. Front Pediatr 2021;9:624045. [PMID: 33681101 DOI: 10.3389/fped.2021.624045] [Reference Citation Analysis]
438 Hou Q, Huang J, Ayansola H, Masatoshi H, Zhang B. Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. Front Immunol 2020;11:623691. [PMID: 33584726 DOI: 10.3389/fimmu.2020.623691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
439 Luo H, Cao G, Luo C, Tan D, Vong CT, Xu Y, Wang S, Lu H, Wang Y, Jing W. Emerging Pharmacotherapy for Inflammatory Bowel Diseases. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106146] [Reference Citation Analysis]
440 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
441 Núñez F P, Krugliak Cleveland N, Quera R, Rubin DT. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol 2021; 27(20): 2521-2530 [PMID: 34092973 DOI: 10.3748/wjg.v27.i20.2521] [Reference Citation Analysis]
442 Yuan Z, Yang L, Zhang X, Ji P, Hua Y, Wei Y. Huang-Lian-Jie-Du Decoction Ameliorates Acute Ulcerative Colitis in Mice via Regulating NF-κB and Nrf2 Signaling Pathways and Enhancing Intestinal Barrier Function. Front Pharmacol 2019;10:1354. [PMID: 31849642 DOI: 10.3389/fphar.2019.01354] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
443 Kayal M, Saha A, Poojary P, Paramsothy S, Hirten R, Cohen L, Gallinger Z, Mehandru S, Cho J, Greenstein A, Nadkarni G, Dubinsky MC, Colombel JF, Cohen B, Ungaro R. Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. Int J Colorectal Dis 2019;34:1771-9. [PMID: 31512019 DOI: 10.1007/s00384-019-03375-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
444 Singh K, Gobert AP, Coburn LA, Barry DP, Allaman M, Asim M, Luis PB, Schneider C, Milne GL, Boone HH, Shilts MH, Washington MK, Das SR, Piazuelo MB, Wilson KT. Dietary Arginine Regulates Severity of Experimental Colitis and Affects the Colonic Microbiome. Front Cell Infect Microbiol 2019;9:66. [PMID: 30972302 DOI: 10.3389/fcimb.2019.00066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
445 Capecchi R, Migliorini P, Zanzi F, Maltinti S, Puxeddu I, de Bortoli N, Bellini M, Costa F, Marchi S, Bertani L. Ig Glycosylation in Ulcerative Colitis: It's Time for New Biomarkers. Front Pharmacol 2021;12:654319. [PMID: 33897440 DOI: 10.3389/fphar.2021.654319] [Reference Citation Analysis]
446 Nardone OM, Rispo A, Testa A, Imperatore N, Pellegrini L, Guarino AD, Ricciolino S, Patturelli M, De Palma G, Castiglione F. The impact of a dedicated contact centre on the clinical outcome of patients with inflammatory bowel disease during the COVID-19 outbreak. Therap Adv Gastroenterol 2020;13:1756284820959586. [PMID: 33024453 DOI: 10.1177/1756284820959586] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
447 D'Haens GRAM, Lindsay JO, Panaccione R, Schreiber S. Ulcerative Colitis: Shifting Sands. Drugs R D 2019;19:227-34. [PMID: 30827006 DOI: 10.1007/s40268-019-0263-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
448 Li T, Zou QP, Huang F, Cheng GG, Mao ZW, Wang T, Dong FW, Li BJ, He HP, Li YP. Flower extract of Caragana sinica. ameliorates DSS-induced ulcerative colitis by affecting TLR4/NF-κB and TLR4/MAPK signaling pathway in a mouse model. Iran J Basic Med Sci 2021;24:595-603. [PMID: 34249260 DOI: 10.22038/IJBMS.2021.53847.12106] [Reference Citation Analysis]
449 Liu X, Li Y, Wu K, Shi Y, Chen M. Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2021;2021:6612970. [PMID: 33981340 DOI: 10.1155/2021/6612970] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
450 Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2021. [PMID: 34854095 DOI: 10.1111/apt.16712] [Reference Citation Analysis]
451 Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Therap Adv Gastroenterol 2020;13:1756284820941179. [PMID: 32922513 DOI: 10.1177/1756284820941179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
452 Rasmussen NF, Bech BH, Rubin KH, Andersen V. Associations between participation in, intensity of, and time spent on leisure time physical activity and risk of inflammatory bowel disease among older adults (PA-IBD): a prospective cohort study. BMC Public Health 2021;21:634. [PMID: 33794834 DOI: 10.1186/s12889-021-10492-7] [Reference Citation Analysis]
453 Lu JZ, Ye D, Ma BL. Constituents, Pharmacokinetics, and Pharmacology of Gegen-Qinlian Decoction. Front Pharmacol 2021;12:668418. [PMID: 34025427 DOI: 10.3389/fphar.2021.668418] [Reference Citation Analysis]
454 Zhang N, Liu J, Guo X, Li S, Wang F, Wang M. Armillaria luteo-virens Sacc Ameliorates Dextran Sulfate Sodium Induced Colitis through Modulation of Gut Microbiota and Microbiota-Related Bile Acids. Nutrients 2021;13:3926. [PMID: 34836184 DOI: 10.3390/nu13113926] [Reference Citation Analysis]
455 Zhao H, Qian YZ, Qian HH. Interleukin-12B gene rs6887695 and rs2288831 polymorphisms are associated with an increased risk of ulcerative colitis development in Chinese Han population: A case-control study. J Clin Lab Anal 2020;34:e23472. [PMID: 32666631 DOI: 10.1002/jcla.23472] [Reference Citation Analysis]
456 Kiss S, Németh D, Hegyi P, Földi M, Szakács Z, Erőss B, Tinusz B, Hegyi PJ, Sarlós P, Alizadeh H. Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. BMJ Open 2021;11:e042374. [PMID: 34011580 DOI: 10.1136/bmjopen-2020-042374] [Reference Citation Analysis]
457 Uzzan M, Ko HM, Rosenstein AK, Pourmand K, Colombel JF, Mehandru S. Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells. Ann N Y Acad Sci 2018;1415:5-10. [PMID: 29291255 DOI: 10.1111/nyas.13577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
458 He N, Wang Y, Zhou Z, Liu N, Jung S, Lee MS, Li S. Preventive and Prebiotic Effect of α-Galacto-Oligosaccharide against Dextran Sodium Sulfate-Induced Colitis and Gut Microbiota Dysbiosis in Mice. J Agric Food Chem 2021;69:9597-607. [PMID: 34378931 DOI: 10.1021/acs.jafc.1c03792] [Reference Citation Analysis]
459 Axelrad JE, Cadwell KH, Colombel JF, Shah SC. Systematic review: gastrointestinal infection and incident inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:1222-32. [PMID: 32372471 DOI: 10.1111/apt.15770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
460 Martins KR, Araújo JM, Cruz ÁC, Luiz-Ferreira A. EPIDEMIOLOGIC ASPECTS OF INFLAMMATORY BOWEL DISEASE IN THE WESTERN REGION OF MINAS GERAIS STATE. Arq Gastroenterol 2021;58:377-83. [PMID: 34705974 DOI: 10.1590/S0004-2803.202100000-63] [Reference Citation Analysis]
461 Al Sulais E, AlAmeel T. Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease. Biologics 2020;14:1-11. [PMID: 32021084 DOI: 10.2147/BTT.S236433] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
462 Sandborn WJ, Armuzzi A, Liguori G, Irving PM, Sharara AI, Mundayat R, Lawendy N, Woolcott JC, Danese S. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflamm Bowel Dis 2021:izab278. [PMID: 34958359 DOI: 10.1093/ibd/izab278] [Reference Citation Analysis]
463 Zhang XY, Zhao HM, Liu Y, Lu XY, Li YZ, Pan QH, Wang HY, Ge W, Liu DY. Sishen Pill Maintained Colonic Mucosal Barrier Integrity to Treat Ulcerative Colitis via Rho/ROCK Signaling Pathway. Evid Based Complement Alternat Med 2021;2021:5536679. [PMID: 34925530 DOI: 10.1155/2021/5536679] [Reference Citation Analysis]
464 Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract 2019;2019:3108025. [PMID: 31565051 DOI: 10.1155/2019/3108025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
465 Cheng C, Zhang W, Zhang C, Ji P, Wu X, Sha Z, Chen X, Wang Y, Chen Y, Cheng H, Shi L. Hyperoside Ameliorates DSS-Induced Colitis through MKRN1-Mediated Regulation of PPARγ Signaling and Th17/Treg Balance. J Agric Food Chem 2021;69:15240-51. [PMID: 34878764 DOI: 10.1021/acs.jafc.1c06292] [Reference Citation Analysis]
466 Reinisch W, Sandborn WJ, Danese S, Hébuterne X, Kłopocka M, Tarabar D, Vaňásek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hoy M, Goetsch M, Bliss C, Gupta C, Cataldi F, Vermeire S. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. J Crohns Colitis 2021;15:938-49. [PMID: 33599720 DOI: 10.1093/ecco-jcc/jjab023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
467 Bravo F, Macpherson JA, Slack E, Patuto N, Cahenzli J, McCoy KD, Macpherson AJ, Juillerat P; SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. Clin Transl Gastroenterol 2021;12:e00298. [PMID: 33735154 DOI: 10.14309/ctg.0000000000000298] [Reference Citation Analysis]
468 Baghaei A, Emami MH, Adibi P, Tavakkoli H, Daghaghzadeh H, Tamizifar B, Akbarpour MJ, Hojjatpour B. Inflammatory Bowel Disease Registry and Monitoring: Feasibility Study and Application (Isfahan Inflammatory Bowel Disease Surveillance Project). Int J Prev Med 2019;10:190. [PMID: 31807260 DOI: 10.4103/ijpvm.IJPVM_316_17] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
469 Shao BZ, Wang SL, Pan P, Yao J, Wu K, Li ZS, Bai Y, Linghu EQ. Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation. Inflammation. 2019;42:1147-1159. [PMID: 30937839 DOI: 10.1007/s10753-019-01008-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
470 Blesl A, Binder L, Högenauer C, Wenzl H, Borenich A, Pregartner G, Berghold A, Mestel S, Kump P, Baumann-Durchschein F, Petritsch W. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther 2021;54:667-77. [PMID: 34151449 DOI: 10.1111/apt.16478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
471 Yang B, Li M, Wang S, Ross RP, Stanton C, Zhao J, Zhang H, Chen W. Lactobacillus ruminis Alleviates DSS-Induced Colitis by Inflammatory Cytokines and Gut Microbiota Modulation. Foods 2021;10:1349. [PMID: 34208038 DOI: 10.3390/foods10061349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Bangma A, Voskuil MD, Uniken Venema WTC, Brugge H, Hu S, Lanting P, Franke L, Dijkstra G, Festen EAM, Weersma RK. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:1105-15. [PMID: 32363635 DOI: 10.1111/apt.15762] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
473 Ge CY, Wei LY, Tian Y, Wang HH. A Seven-NF-κB-Related Gene Signature May Distinguish Patients with Ulcerative Colitis-Associated Colorectal Carcinoma. Pharmgenomics Pers Med 2020;13:707-18. [PMID: 33299340 DOI: 10.2147/PGPM.S274258] [Reference Citation Analysis]
474 Ghosh S, Sensky T, Casellas F, Rioux LC, Ahmad T, Márquez JR, Vanasek T, Gubonina I, Sezgin O, Ardizzone S, Kligys K, Petersson J, Suzuki Y, Peyrin-Biroulet L. A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool. J Crohns Colitis 2020:jjaa159. [PMID: 32722760 DOI: 10.1093/ecco-jcc/jjaa159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
475 Li Q, Qu X, Pang X, Song Y, Chen L, Xiao Q, Sun L, Wang X, Zhang H, Qi D, Wang Z. Berberine Protects Mice Against Dextran Sulfate Sodium-Induced Colitis by Activating mTORC1 Pathway. Front Pharmacol 2019;10:786. [PMID: 31354497 DOI: 10.3389/fphar.2019.00786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
476 Amiot A, Seksik P, Reimund J, Nachury M, Altwegg R, Bourreille A, Viennot S, Fumery M, Roblin X, Serrero M, Allez M, Painchart C, Chanteloup E, Vuitton L, Fotsing G, Buisson A, Coulibaly B, Nancey S, Gilletta C, Plastaras L, Abitbol V, Guillo L, Simon M, Nahon S, Laharie D, Peyrin-biroulet L, Bouguen G, Amiot A, Gagniere C, Nachury M, Wils P, Bouhnik Y, Stefanescu C, Treton X, Martins C, Uzzan M, Serrero M, Guillo L, Roblin X, Tedesco ED, Beaugerie L, Seksik P, Bourrier A, Landmann C, Kirchgesner J, Sokol H, Buisson A, Nancey S, Boschetti G, Gay C, Danion P, Flourié B, Abitbol V, Malamut G, Reimund J, Caron B, Vuitton L, Peyrin-biroulet L, Zallot C, Gilletta C, Allez M, Gornet J, Baudry C, Viennot S, Bourreille A, Trang-poisson C, Boualit M, Painchart C, Plastaras L, Altwegg R, Boivineau L, Fumery M, Laharie D, Riviere P, Poullenot F, Coffin B, Duboc H, Nahon S, Simon M, Coulibaly B, Chanteloup E, Fotsing G. Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.011] [Reference Citation Analysis]
477 Su L, Su Y, An Z, Zhang P, Yue Q, Zhao C, Sun X, Zhang S, Liu X, Li K, Zhao L. Fermentation products of Danshen relieved dextran sulfate sodium-induced experimental ulcerative colitis in mice. Sci Rep 2021;11:16210. [PMID: 34376708 DOI: 10.1038/s41598-021-94594-7] [Reference Citation Analysis]
478 Gao C, Liu L, Zhou Y, Bian Z, Wang S, Wang Y. Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease. Chin Med 2019;14:23. [PMID: 31236131 DOI: 10.1186/s13020-019-0245-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
479 Wang Q, Wang Z, Zhang Z, Zhang W, Zhang M, Shen Z, Ye Y, Jiang K, Wang S. Landscape of cell heterogeneity and evolutionary trajectory in ulcerative colitis-associated colon cancer revealed by single-cell RNA sequencing. Chin J Cancer Res 2021;33:271-88. [PMID: 34158745 DOI: 10.21147/j.issn.1000-9604.2021.02.13] [Reference Citation Analysis]
480 Yin J, Wei L, Wang N, Li X, Miao M. Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis. Journal of Ethnopharmacology 2022. [DOI: 10.1016/j.jep.2022.115041] [Reference Citation Analysis]
481 Zheng L, Wen XL, Dai YC. Mechanism of Jianpi Qingchang Huashi Recipe in treating ulcerative colitis: A study based on network pharmacology and molecular docking. World J Clin Cases 2021; 9(26): 7653-7670 [PMID: 34621817 DOI: 10.12998/wjcc.v9.i26.7653] [Reference Citation Analysis]
482 Caër C, Gorreja F, Forsskåhl SK, Brynjolfsson SF, Szeponik L, Magnusson MK, Börjesson LG, Block M, Bexe-Lindskog E, Wick MJ. TREM-1+ Macrophages Define a Pathogenic Cell Subset in the Intestine of Crohn's Disease Patients. J Crohns Colitis 2021;15:1346-61. [PMID: 33537747 DOI: 10.1093/ecco-jcc/jjab022] [Reference Citation Analysis]
483 Yun HF, Liu R, Han D, Zhao X, Guo JW, Yan FJ, Zhang C, Sun HW, Liang GQ, Zhang GX. Pingkui Enema Alleviates TNBS-Induced Ulcerative Colitis by Regulation of Inflammatory Factors, Gut Bifidobacterium, and Intestinal Mucosal Barrier in Rats. Evid Based Complement Alternat Med 2020;2020:3896948. [PMID: 32831864 DOI: 10.1155/2020/3896948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
484 Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31496-8. [PMID: 33127596 DOI: 10.1016/j.cgh.2020.10.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874-883. [PMID: 30908297 DOI: 10.14309/ajg.0000000000000183] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 33.5] [Reference Citation Analysis]
486 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
487 Liu L, Liang L, Liang H, Wang M, Lu B, Xue M, Deng J, Chen Y. Fusobacterium nucleatum Aggravates the Progression of Colitis by Regulating M1 Macrophage Polarization via AKT2 Pathway. Front Immunol 2019;10:1324. [PMID: 31249571 DOI: 10.3389/fimmu.2019.01324] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
488 Juliao-Baños F, Puentes F, López R, Saffon MA, Reyes G, Parra V, Galiano MT, Barraza M, Molano J, Álvarez E, Corrales R, Vargas LE, Gil F, Álvarez P, Limas L, Prieto R, Yance P, Díaz F, Bareño J; Grupo del Registro Colombiano de Enfermedad Inflamatoria Intestinal., Grupo Registro Colombiano de Enfermedad Inflamatoria Intestinal. Characterization of inflammatory bowel disease in Colombia: Results of a national register. Rev Gastroenterol Mex (Engl Ed) 2021;86:153-62. [PMID: 32723624 DOI: 10.1016/j.rgmx.2020.05.005] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
489 Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open 2021;11:e049740. [PMID: 34772750 DOI: 10.1136/bmjopen-2021-049740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
490 Zhuang H, Lv Q, Zhong C, Cui Y, He L, Zhang C, Yu J. Tiliroside Ameliorates Ulcerative Colitis by Restoring the M1/M2 Macrophage Balance via the HIF-1α/glycolysis Pathway. Front Immunol 2021;12:649463. [PMID: 33868286 DOI: 10.3389/fimmu.2021.649463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
491 He W, Ni W, Zhao J. Enterococcus faecium Alleviates Gut Barrier Injury in C57BL/6 Mice with Dextran Sulfate Sodium-Induced Ulcerative Colitis. Gastroenterol Res Pract 2021;2021:2683465. [PMID: 34868304 DOI: 10.1155/2021/2683465] [Reference Citation Analysis]
492 Andersen V, Möller S, Jensen PB, Møller FT, Green A. Caesarean Delivery and Risk of Chronic Inflammatory Diseases (Inflammatory Bowel Disease, Rheumatoid Arthritis, Coeliac Disease, and Diabetes Mellitus): A Population Based Registry Study of 2,699,479 Births in Denmark During 1973-2016. Clin Epidemiol 2020;12:287-93. [PMID: 32210632 DOI: 10.2147/CLEP.S229056] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
493 Hanzel J, Bukkems LH, Gecse KB, D'Haens GR, Mathôt RAA. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2021;54:1309-19. [PMID: 34559426 DOI: 10.1111/apt.16609] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
494 Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14:254-266. [PMID: 31403666 DOI: 10.1093/ecco-jcc/jjz131] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 25.0] [Reference Citation Analysis]
495 D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J 2021;9:451-60. [PMID: 33961734 DOI: 10.1002/ueg2.12069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
496 Ibaraki H, Hatakeyama N, Arima N, Takeda A, Seta Y, Kanazawa T. Systemic delivery of siRNA to the colon using peptide modified PEG-PCL polymer micelles for the treatment of ulcerative colitis. Eur J Pharm Biopharm 2021:S0939-6411(21)00358-1. [PMID: 34963657 DOI: 10.1016/j.ejpb.2021.12.009] [Reference Citation Analysis]
497 Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00298-3. [PMID: 34798039 DOI: 10.1016/S2468-1253(21)00298-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
498 Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 59] [Cited by in F6Publishing: 76] [Article Influence: 29.5] [Reference Citation Analysis]
499 Kirchberger-Tolstik T, Pradhan P, Vieth M, Grunert P, Popp J, Bocklitz TW, Stallmach A. Towards an Interpretable Classifier for Characterization of Endoscopic Mayo Scores in Ulcerative Colitis Using Raman Spectroscopy. Anal Chem. 2020;92:13776-13784. [PMID: 32965101 DOI: 10.1021/acs.analchem.0c02163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
500 Ding P, Liu J, Li Q, Lu Q, Li J, Shi R, Shi L, Mao T, Ge D, Niu H, Peng G, Wang Z. Investigation of the Active Ingredients and Mechanism of Hudi Enteric-Coated Capsules in DSS-Induced Ulcerative Colitis Mice Based on Network Pharmacology and Experimental Verification. Drug Des Devel Ther 2021;15:4259-73. [PMID: 34675488 DOI: 10.2147/DDDT.S326029] [Reference Citation Analysis]
501 Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, Kamal K, Bruss A, Beniwal-Patel P, Fox C, Patel A, Bahur B, Jain A, Stein D, Naik S, Dubinsky MC. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. J Crohns Colitis 2019;13:963-9. [PMID: 31087100 DOI: 10.1093/ecco-jcc/jjz041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
502 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Reference Citation Analysis]
503 Shen Y, Shi L, Zhang J, Zhu H, Yao Y, Liu Z, Zou X, Zhang X. Thromboelastography in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2020;2020:3245657. [PMID: 32565780 DOI: 10.1155/2020/3245657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
504 Zhang C, Qin J, Zhang S, Zhang N, Tan B, Siwko S, Zhang Y, Wang Q, Chen J, Qian M, Liu M, Du B. ADP/P2Y1 aggravates inflammatory bowel disease through ERK5-mediated NLRP3 inflammasome activation. Mucosal Immunol 2020;13:931-45. [PMID: 32518369 DOI: 10.1038/s41385-020-0307-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
505 Marafini I, Di Fusco D, Dinallo V, Franzè E, Stolfi C, Sica G, Monteleone G, Monteleone I. NPD-0414-2 and NPD-0414-24, Two Chemical Entities Designed as Aryl Hydrocarbon Receptor (AhR) Ligands, Inhibit Gut Inflammatory Signals. Front Pharmacol 2019;10:380. [PMID: 31031628 DOI: 10.3389/fphar.2019.00380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
506 Kamath C, Brenner EJ. The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic. Curr Res Pharmacol Drug Discov 2022;3:100101. [PMID: 35496814 DOI: 10.1016/j.crphar.2022.100101] [Reference Citation Analysis]
507 Liu C, Huang S, Wu Z, Li T, Li N, Zhang B, Han D, Wang S, Zhao J, Wang J. Cohousing-mediated microbiota transfer from milk bioactive components-dosed mice ameliorate colitis by remodeling colonic mucus barrier and lamina propria macrophages. Gut Microbes 2021;13:1-23. [PMID: 33789528 DOI: 10.1080/19490976.2021.1903826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
508 Liu C, Li Y, Chen Y, Huang S, Wang X, Luo S, Su Y, Zhou L, Luo X. Baicalein Restores the Balance of Th17/Treg Cells via Aryl Hydrocarbon Receptor to Attenuate Colitis. Mediators Inflamm 2020;2020:5918587. [PMID: 33082710 DOI: 10.1155/2020/5918587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
509 Liso M, De Santis S, Scarano A, Verna G, Dicarlo M, Galleggiante V, Campiglia P, Mastronardi M, Lippolis A, Vacca M, Sobolewski A, Serino G, Butelli E, De Angelis M, Martin C, Santino A, Chieppa M. A Bronze-Tomato Enriched Diet Affects the Intestinal Microbiome under Homeostatic and Inflammatory Conditions. Nutrients 2018;10:E1862. [PMID: 30513801 DOI: 10.3390/nu10121862] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
510 Colombel JF. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. Inflamm Bowel Dis 2018;24:2173-82. [PMID: 29788127 DOI: 10.1093/ibd/izy150] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
511 Rubin DT, Reinisch W, Greuter T, Kotze PG, Pinheiro M, Mundayat R, Maller E, Fellmann M, Lawendy N, Modesto I, Vavricka SR, Lichtenstein GR. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211005708. [PMID: 34035832 DOI: 10.1177/17562848211005708] [Reference Citation Analysis]
512 Yang H, Gan D, Li Y, Wang X, Jin L, Qin K, Cui C, Wu J, Wang Z. Quyushengxin Formula Causes Differences in Bacterial and Phage Composition in Ulcerative Colitis Patients. Evid Based Complement Alternat Med 2020;2020:5859023. [PMID: 32454865 DOI: 10.1155/2020/5859023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
513 Dai L, Tang Y, Zhou W, Dang Y, Sun Q, Tang Z, Zhu M, Ji G. Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment. Front Pharmacol 2020;11:620724. [PMID: 33628183 DOI: 10.3389/fphar.2020.620724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
514 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
515 Rao Q, Ma GC, Wu H, Li M, Xu W, Wang GJ, Wang D, Zhang CE, Ma ZJ, Zhang ZT. Dendritic cell combination therapy reduces the toxicity of triptolide and ameliorates colitis in murine models. Drug Deliv 2022;29:679-91. [PMID: 35225120 DOI: 10.1080/10717544.2022.2044935] [Reference Citation Analysis]
516 Han X, Ding S, Jiang H, Liu G. Roles of Macrophages in the Development and Treatment of Gut Inflammation. Front Cell Dev Biol 2021;9:625423. [PMID: 33738283 DOI: 10.3389/fcell.2021.625423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
517 McManus D, Novaira HJ, Hamers AAJ, Pillai AB. Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E. J Vis Exp 2019. [PMID: 31609324 DOI: 10.3791/59821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
518 Calvet X, Argüelles-Arias F, López-Sanromán A, Cea-Calvo L, Juliá B, de Santos CR, Carpio D. Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain. Patient Prefer Adherence 2018;12:1815-23. [PMID: 30271125 DOI: 10.2147/PPA.S175026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
519 Dolinger M, Verstockt B. Ulcerative colitis, a transmural disease requiring an accurate IUS assessment in the current treat-to-target era. United European Gastroenterol J 2022. [PMID: 35230746 DOI: 10.1002/ueg2.12215] [Reference Citation Analysis]
520 Caio G, Lungaro L, Caputo F, Muccinelli M, Marcello MC, Zoli E, Volta U, De Giorgio R, Zoli G. Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature. BMJ Open Gastroenterol 2021;8:e000587. [PMID: 33722804 DOI: 10.1136/bmjgast-2020-000587] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
521 Artom M, Czuber-Dochan W, Sturt J, Proudfoot H, Roberts D, Norton C. Cognitive-behavioural therapy for the management of inflammatory bowel disease-fatigue: a feasibility randomised controlled trial. Pilot Feasibility Stud 2019;5:145. [PMID: 31890258 DOI: 10.1186/s40814-019-0538-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
522 He Q. Cardiocerebral and peripheral vascular risks in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2019; 27(5): 341-346 [DOI: 10.11569/wcjd.v27.i5.341] [Reference Citation Analysis]
523 Xu Z, Zhang X, Wang W, Zhang D, Ma Y, Zhang D, Chen M. Fructus Mume (Wu Mei) Attenuates Acetic Acid-Induced Ulcerative Colitis by Regulating Inflammatory Cytokine, Reactive Oxygen Species, and Neuropeptide Levels in Model Rats. J Med Food 2022;25:389-401. [PMID: 35438553 DOI: 10.1089/jmf.2021.K.0155] [Reference Citation Analysis]
524 Chao L, Lin J, Zhou J, Du H, Chen X, Liu M, Qu Q, Lv W, Guo S. Polyphenol Rich Forsythia suspensa Extract Alleviates DSS-Induced Ulcerative Colitis in Mice through the Nrf2-NLRP3 Pathway. Antioxidants 2022;11:475. [DOI: 10.3390/antiox11030475] [Reference Citation Analysis]
525 Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, Rosewarne CP, Bickley C, Peters C, Schoeman MN, Conlon MA, Roberts-Thomson IC, Andrews JM. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. JAMA. 2019;321:156-164. [PMID: 30644982 DOI: 10.1001/jama.2018.20046] [Cited by in Crossref: 230] [Cited by in F6Publishing: 206] [Article Influence: 76.7] [Reference Citation Analysis]
526 Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Database Syst Rev 2022;4:CD007216. [PMID: 35388476 DOI: 10.1002/14651858.CD007216.pub2] [Reference Citation Analysis]
527 Matsuda K, Hashiguchi Y, Asako K, Okada Y, Ohno K, Tsukamoto M, Fukushima Y, Shimada R, Ozawa T, Hayama T, Nozawa K, Fukagawa T, Sasajima Y. Afferent limb syndrome after total proctocolectomy and ileal pouch-anal canal anastomosis. Surg Case Rep 2020;6:209. [PMID: 32797327 DOI: 10.1186/s40792-020-00968-w] [Reference Citation Analysis]
528 Xu L, Zhang J, Wang Y, Zhang Z, Wang F, Tang X. Uncovering the mechanism of Ge-Gen-Qin-Lian decoction for treating ulcerative colitis based on network pharmacology and molecular docking verification. Biosci Rep 2021;41:BSR20203565. [PMID: 33409535 DOI: 10.1042/BSR20203565] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
529 Bai R, Sun D, Chen M, Shi X, Luo L, Yao Z, Liu Y, Ge X, Gao X, Hu GF, Zhou W, Sheng J, Xu Z. Myeloid cells protect intestinal epithelial barrier integrity through the angiogenin/plexin-B2 axis. EMBO J 2020;39:e103325. [PMID: 32510170 DOI: 10.15252/embj.2019103325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
530 Wei Y, Jiang N, Liu T, Liu C, Xiao W, Liang L, Li T, Yu Y. The comparison of extraction methods of ganjiang decoction based on fingerprint, quantitative analysis and pharmacodynamics. Chin Med 2020;15:81. [PMID: 32774446 DOI: 10.1186/s13020-020-00355-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
531 Dubinsky MC, Magro F, Steinwurz F, Hudesman DP, Kinnucan JA, Ungaro RC, Neurath MF, Kulisek N, Paulissen J, Su C, Ponce de Leon D, Regueiro M. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis 2022:izac061. [PMID: 35380664 DOI: 10.1093/ibd/izac061] [Reference Citation Analysis]
532 El-Sherbiny M, Eisa NH, Abo El-Magd NF, Elsherbiny NM, Said E, Khodir AE. Anti-inflammatory/anti-apoptotic impact of betulin attenuates experimentally induced ulcerative colitis: An insight into TLR4/NF-kB/caspase signalling modulation. Environ Toxicol Pharmacol 2021;88:103750. [PMID: 34597787 DOI: 10.1016/j.etap.2021.103750] [Reference Citation Analysis]
533 Li R, Chen C, Liu B, Shi W, Shimizu K, Zhang C. Bryodulcosigenin a natural cucurbitane-type triterpenoid attenuates dextran sulfate sodium (DSS)-induced colitis in mice. Phytomedicine 2022;94:153814. [PMID: 34798522 DOI: 10.1016/j.phymed.2021.153814] [Reference Citation Analysis]
534 Cha N, Oshima N, Kishimoto K, Kotani S, Okimoto E, Yazaki T, Sonoyama H, Oka A, Mishima Y, Shibagaki K, Tobita H, Kawashima K, Ishimura N, Ishihara S. Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-139] [Reference Citation Analysis]
535 Almofarreh A, Sheerah HA, Arafa A, Ahamed SS, Alzeer O, Al-hunaishi W, Mhimed MM, Al-hazmi A, Lim SH. Beverage Consumption and Ulcerative Colitis: A Case-Control Study from Saudi Arabia. IJERPH 2022;19:2287. [DOI: 10.3390/ijerph19042287] [Reference Citation Analysis]
536 Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D, Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J; GO SWIBREG study group. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol 2021;56:1304-11. [PMID: 34415803 DOI: 10.1080/00365521.2021.1963466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
537 Huang BB, Han LC, Liu GF, Lv XD, Gu GL, Li SQ, Chen L, Wang HQ, Zhan LL, Lv XP. Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report. World J Gastroenterol 2020; 26(46): 7425-7435 [PMID: 33362394 DOI: 10.3748/wjg.v26.i46.7425] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
538 Zheng X, Mai L, Wang T, Xu Y, Su Z, Chen J, Zeng H, Xie Y. Brusatol-Enriched Brucea javanica Oil Ameliorated Dextran Sulfate Sodium-Induced Colitis in Mice: Involvement of NF-κB and RhoA/ROCK Signaling Pathways. Biomed Res Int 2021;2021:5561221. [PMID: 34414236 DOI: 10.1155/2021/5561221] [Reference Citation Analysis]
539 Furfaro F, Dal Buono A, Allocca M, D'Amico F, Zilli A, Gabbiadini R, Danese S. Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale? Life (Basel) 2021;11:649. [PMID: 34357022 DOI: 10.3390/life11070649] [Reference Citation Analysis]
540 Calderón-Torres CM, Sarabia-Curz L, Ledesma-Soto Y, Murguía-Romero M, Terrazas LI. Denitrase activity of Debaryomyces hansenii reduces the oxidized compound 3-nitrotyrosine in mice liver with colitis. Exp Ther Med 2019;17:3748-54. [PMID: 31007730 DOI: 10.3892/etm.2019.7395] [Reference Citation Analysis]
541 Bekkers M, Stojkovic B, Kaiko GE. Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease. Int J Mol Sci 2021;22:11243. [PMID: 34681902 DOI: 10.3390/ijms222011243] [Reference Citation Analysis]
542 Zhao C, Huang H, Pan Q, Huang W, Peng W, Xu H, Feng Z, Du Y, Nie Y, Zhou Y. Unconjugated Bilirubin Attenuates DSS-Induced Colitis Potentially via Enhancement of Bilirubin Reabsorption. Front Pharmacol 2021;12:654808. [PMID: 34093187 DOI: 10.3389/fphar.2021.654808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
543 Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481-491.e483. [PMID: 32425234 DOI: 10.1053/j.gastro.2020.05.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 269] [Article Influence: 132.5] [Reference Citation Analysis]
544 Stallmach A, Grunert P, Stallhofer J, Löffler B, Baier M, Rödel J, Kiehntopf M, Neugebauer S, Pieper DH, Junca H, Tannapfel A, Merkel U, Schumacher U, Breternitz-Gruhne M, Heller T, Schauer A, Hartmann M, Steube A. Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials 2022;23:173. [PMID: 35193638 DOI: 10.1186/s13063-022-06095-1] [Reference Citation Analysis]
545 Yau YY, Wasinger VC, Hirten RP, Chuang E, Huntsman M, Stylli J, Shimizu J, Yajnik V, Smith J, Lee SN, Singh S, Wahl C, Leong RW, Sands BE. Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. Inflamm Bowel Dis 2021;27:S17-24. [PMID: 34791290 DOI: 10.1093/ibd/izab179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
546 Wang Y, Zhang J, Xu L, Ma J, Lu M, Ma J, Liu Z, Wang F, Tang X. Modified Gegen Qinlian Decoction Regulates Treg/Th17 Balance to Ameliorate DSS-Induced Acute Experimental Colitis in Mice by Altering the Gut Microbiota. Front Pharmacol 2021;12:756978. [PMID: 34803700 DOI: 10.3389/fphar.2021.756978] [Reference Citation Analysis]
547 Huang J, Zheng Y, Ma J, Ma J, Lu M, Ma X, Wang F, Tang X. Exploration of the Potential Mechanisms of Wumei Pill for the Treatment of Ulcerative Colitis by Network Pharmacology. Gastroenterol Res Pract 2021;2021:4227668. [PMID: 34970312 DOI: 10.1155/2021/4227668] [Reference Citation Analysis]
548 Shen Y, Cui Y, Shi Z, Wu H, Wang Z, Wu L, Lu Y, Huang Y, Liu Y, Long J, Lin Y, Ma Z. Investigating the influence of moxibustion on colonic mucosal barrier in rats with dextran sulfate sodium-induced ulcerative colitis. J Acupunct Tuina Sci 2022;20:1-11. [DOI: 10.1007/s11726-022-1286-8] [Reference Citation Analysis]
549 Li C, Zhou Y, Rychahou P, Weiss HL, Lee EY, Perry CL, Barrett TA, Wang Q, Evers BM. SIRT2 Contributes to the Regulation of Intestinal Cell Proliferation and Differentiation. Cell Mol Gastroenterol Hepatol 2020;10:43-57. [PMID: 31954883 DOI: 10.1016/j.jcmgh.2020.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
550 Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol 2020;13:211-20. [PMID: 32606883 DOI: 10.2147/CEG.S248597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
551 Manthey CF, Reher D, Huber S. [What is confirmed in the treatment of chronic inflammatory bowel diseases]. Internist (Berl) 2021. [PMID: 34727190 DOI: 10.1007/s00108-021-01207-6] [Reference Citation Analysis]
552 Liu Y, Huang W, Zhu Y, Zhao T, Xiao F, Wang Y, Lu B. Acteoside, the Main Bioactive Compound in Osmanthus fragrans Flowers, Palliates Experimental Colitis in Mice by Regulating the Gut Microbiota. J Agric Food Chem . [DOI: 10.1021/acs.jafc.1c07583] [Reference Citation Analysis]
553 Zhuang X, Liu C, Zhan S, Tian Z, Li N, Mao R, Zeng Z, Chen M. Gut Microbiota Profile in Pediatric Patients With Inflammatory Bowel Disease: A Systematic Review. Front Pediatr 2021;9:626232. [PMID: 33604319 DOI: 10.3389/fped.2021.626232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
554 Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R. Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body. Front Immunol 2021;12:578386. [PMID: 33717063 DOI: 10.3389/fimmu.2021.578386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
555 Le Berre C, Loy L, Lönnfors S, Avedano L, Piovani D. Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations. World J Gastroenterol 2020; 26(29): 4343-4355 [PMID: 32848338 DOI: 10.3748/wjg.v26.i29.4343] [Reference Citation Analysis]
556 Chen YL, Zheng YY, Dai YC, Zhang YL, Tang ZP. Systems pharmacology approach reveals protective mechanisms of Jian-Pi Qing-Chang decoction on ulcerative colitis. World J Gastroenterol 2019; 25(21): 2603-2622 [PMID: 31210713 DOI: 10.3748/wjg.v25.i21.2603] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
557 Li N, Sun W, Zhou X, Gong H, Chen Y, Chen D, Xiang F. Dihydroartemisinin Protects against Dextran Sulfate Sodium-Induced Colitis in Mice through Inhibiting the PI3K/AKT and NF-κB Signaling Pathways. Biomed Res Int 2019;2019:1415809. [PMID: 31781591 DOI: 10.1155/2019/1415809] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
558 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Reference Citation Analysis]
559 Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Des Devel Ther 2019;13:4091-105. [PMID: 31819376 DOI: 10.2147/DDDT.S182891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
560 Zhang XF, Li P, Ding XL, Chen H, Wang SJ, Jin SB, Guo J, Tian ZB. Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis. Gastroenterol Rep (Oxf) 2021;9:533-42. [PMID: 34925850 DOI: 10.1093/gastro/goab026] [Reference Citation Analysis]
561 Gu D, Zhou S, Yao L, Tan Y, Chi X, Shi D, Guo S, Liu C. Effects of ShenLing BaiZhu San Supplementation on Gut Microbiota and Oxidative Stress in Rats with Ulcerative Colitis. Evid Based Complement Alternat Med 2021;2021:3960989. [PMID: 34630607 DOI: 10.1155/2021/3960989] [Reference Citation Analysis]
562 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
563 Zhou J, Liu J, Gao Y, Shen L, Li S, Chen S. miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis. Front Pharmacol 2021;12:707776. [PMID: 34305614 DOI: 10.3389/fphar.2021.707776] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
564 Ochi M, Niikura R, Otsubo T, Yamada A, Kawai T, Koike K. Comparison of inflammatory bowel disease relapse after top-down or step-up therapy: a population-based cohort study. Int J Colorectal Dis 2021;36:2227-35. [PMID: 34386841 DOI: 10.1007/s00384-021-04007-4] [Reference Citation Analysis]
565 Shao J, Li Z, Gao Y, Zhao K, Lin M, Li Y, Wang S, Liu Y, Chen L. Construction of a "Bacteria-Metabolites" Co-Expression Network to Clarify the Anti-Ulcerative Colitis Effect of Flavonoids of Sophora flavescens Aiton by Regulating the "Host-Microbe" Interaction. Front Pharmacol 2021;12:710052. [PMID: 34721011 DOI: 10.3389/fphar.2021.710052] [Reference Citation Analysis]
566 Collij V, Klaassen MAY, Weersma RK, Vila AV. Gut microbiota in inflammatory bowel diseases: moving from basic science to clinical applications. Hum Genet 2021;140:703-8. [PMID: 32857194 DOI: 10.1007/s00439-020-02218-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
567 Yang Y, Li L, Xu C, Wang Y, Wang Z, Chen M, Jiang Z, Pan J, Yang C, Li X, Song K, Yan J, Xie W, Wu X, Chen Z, Yuan Y, Zheng S, Yan J, Huang J, Qiu F. Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis. Gut 2020:gutjnl-2020-320777. [PMID: 33122176 DOI: 10.1136/gutjnl-2020-320777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
568 Cao Q, Gao X, Lin Y, Yue C, Wang Y, Quan F, Zhang Z, Liu X, Lu Y, Zhan Y, Yang H, Li X, Qin D, Birnbaumer L, Hao K, Yang Y. Thymopentin ameliorates dextran sulfate sodium-induced colitis by triggering the production of IL-22 in both innate and adaptive lymphocytes. Theranostics 2019;9:7490-505. [PMID: 31695782 DOI: 10.7150/thno.35015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
569 Li H, Cao W, Xie J, Che H, Liu L, Dong X, Song L, Xie W. α-D-1,6-glucan from Castanea mollissima Blume alleviates dextran sulfate sodium-induced colitis in vivo. Carbohydrate Polymers 2022;289:119410. [DOI: 10.1016/j.carbpol.2022.119410] [Reference Citation Analysis]
570 Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Reference Citation Analysis]
571 Ibrahim MA, Abdelmonaem AA, Abdel-Gaber SA, Hafez HM, Abdel Hafez SMN, Yehia Abdelzaher W. Rupatadine ameliorated ulcerative colitis in rats via modulation of platelet-activatiweng factor/interleukin-6/vascular endothelial growth factor signalling pathway. J Pharm Pharmacol 2022:rgab170. [PMID: 35134225 DOI: 10.1093/jpp/rgab170] [Reference Citation Analysis]
572 Masu Y, Kanazawa Y, Kakuta Y, Shimoyama Y, Onodera M, Naito T, Moroi R, Kuroha M, Kimura T, Shiga H, Kinouchi Y, Masamune A. Immunoglobulin subtype-coated bacteria are correlated with the disease activity of inflammatory bowel disease. Sci Rep 2021;11:16672. [PMID: 34404881 DOI: 10.1038/s41598-021-96289-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
573 Monstad IL, Solberg IC, Cvancarova M, Hovde O, Henriksen M, Huppertz-Hauss G, Gunther E, Moum BA, Stray N, Vatn M, Hoie O, Jahnsen J. Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis 2021;15:969-79. [PMID: 33367569 DOI: 10.1093/ecco-jcc/jjaa232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
574 Liu D, Saikam V, Skrada KA, Merlin D, Iyer SS. Inflammatory bowel disease biomarkers. Medicinal Research Reviews. [DOI: 10.1002/med.21893] [Reference Citation Analysis]
575 Liao Z, Xie Y, Zhou B, Zou B, Xiao D, Liu W, Cai Y, Liu D, Liao Q, Xie Z. Berberine ameliorates colonic damage accompanied with the modulation of dysfunctional bacteria and functions in ulcerative colitis rats. Appl Microbiol Biotechnol 2020;104:1737-49. [DOI: 10.1007/s00253-019-10307-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
576 Mesonero F, Juliá B, Saldaña R, Savini C, Cañas M, Cea-Calvo L, Feo-Lucas L, Fernández S, Rodríguez-Lago I; ACCU, GETECCU and GETEII. Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients' behaviors. Eur J Gastroenterol Hepatol 2021;33:501-7. [PMID: 32956185 DOI: 10.1097/MEG.0000000000001931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
577 Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, Nachury M, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP, Mariat C, Peyrin-Biroulet L. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Dig Liver Dis 2021:S1590-8658(21)00848-3. [PMID: 34866011 DOI: 10.1016/j.dld.2021.11.008] [Reference Citation Analysis]
578 Paulides E, Cornelissen D, de Vries AC, van der Woude CJ. Inflammatory bowel disease negatively impacts household and family life. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-102027] [Reference Citation Analysis]
579 Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13622] [Reference Citation Analysis]
580 Connor SJ, Sechi A, Andrade M, Deuring JJ, Witcombe D. Ulcerative Colitis Narrative findings: Australian survey data comparing patient and physician disease management views. JGH Open 2021;5:1033-40. [PMID: 34584972 DOI: 10.1002/jgh3.12627] [Reference Citation Analysis]
581 Lees CW, Deuring JJ, Chiorean M, Daperno M, Bonfanti G, Germino R, Brown PB, Modesto I, Edwards RA. Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies. Therap Adv Gastroenterol 2021;14:17562848211054710. [PMID: 35154388 DOI: 10.1177/17562848211054710] [Reference Citation Analysis]
582 Liso M, De Santis S, Verna G, Dicarlo M, Calasso M, Santino A, Gigante I, Eri R, Raveenthiraraj S, Sobolewski A, Palmitessa V, Lippolis A, Mastronardi M, Armentano R, Serino G, De Angelis M, Chieppa M. A Specific Mutation in Muc2 Determines Early Dysbiosis in Colitis-Prone Winnie Mice. Inflamm Bowel Dis 2020;26:546-56. [PMID: 31748792 DOI: 10.1093/ibd/izz279] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
583 Laganà B, Zullo A, Scribano ML, Chimenti MS, Migliore A, Picchianti Diamanti A, Lorenzetti R, Scolieri P, Ridola L, Ortona E, Pierdominici M, Bruzzese V. Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. Front Pharmacol 2019;10:47. [PMID: 30745872 DOI: 10.3389/fphar.2019.00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
584 Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC, Fossmark R. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 2019;49:1301-13. [PMID: 30895635 DOI: 10.1111/apt.15227] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
585 Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflamm Intest Dis 2021;6:117-22. [PMID: 34124183 DOI: 10.1159/000515361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
586 Hagihara K, Mori R, Sekido Y, Ogino T, Hata T, Takahashi H, Miyoshi N, Uemura M, Doki Y, Eguchi H, Mizushima T. Defecation Function After Laparo-Assisted Restorative Proctocolectomy with Ileal Pouch Anal Anastomosis for Ulcerative Colitis. J Laparoendosc Adv Surg Tech A 2021. [PMID: 34569880 DOI: 10.1089/lap.2021.0465] [Reference Citation Analysis]
587 Wang B, Liu T, Liu F, He YL. Pyoderma gangrenosum at multiple sites in a post-colostomy ulcerative colitis patient with chronic hepatitis B virus: A case report. Int Wound J 2020;17:187-90. [PMID: 31663272 DOI: 10.1111/iwj.13255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
588 Tekoriutė P, Matuliauskaitė M, Jonaitis LV. Drug-Induced Intersticial Nephritis. Clinical Case. AML 2021;28:14. [DOI: 10.15388/amed.2021.28.2.14] [Reference Citation Analysis]
589 De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, Biancone L, Calabrese E, Monteleone G. Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. J Clin Med 2021;10:5413. [PMID: 34830694 DOI: 10.3390/jcm10225413] [Reference Citation Analysis]
590 Cao F, Cheng YS, Yu L, Xu YY, Wang Y. Bioinformatics Analysis of Differentially Expressed Genes and Protein-Protein Interaction Networks Associated with Functional Pathways in Ulcerative Colitis. Med Sci Monit 2021;27:e927917. [PMID: 33462173 DOI: 10.12659/MSM.927917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]